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Abstract 
 
In about 10% of citizens of European Union (EU) take antidepressants. In 
Portugal, according to OCDE, the use of antidepressants is higher than EU average. 
During the last decades, a variety of antidepressants, selective serotonin reuptake 
inhibitor (SSRI), as fluoxetine (FLUX), and serotonin norepinephrine reuptake inhibitor 
(SNRI), as venlafaxine (VEN), were recognized as an important source of 
environmental contamination and increasing concern emerged regarding their potential 
ecological impact. Pharmaceutical targets are highly conserved among vertebrates 
suggesting that aquatic animals, as fish species, are likely to be affected by 
environmental exposure even at low concentration (ng/L). Main therapeutic properties 
of these psychotropic drugs are based upon modulation of important monoamine 
neurotransmitters, as serotonin and dopamine. They block monoamine reuptake in the 
presynaptic cells, which leads to an increase in the concentration of serotonin and/or 
dopamine and norepinephrine within the synapses. Recent studies have focused on 
effects in freshwater fish, but information on marine fish is scarce. However, knowledge 
of the effects of PP on the neurotransmitter and neuroendocrine system is needed, 
which is important to evaluate risks for aquatic vertebrates, and finally on 
environmental and human health.  
In this work, we explored and evaluated the transcriptional levels of 
neurotransmitters and receptors mRNA in the brain of the Dicentrarchus labrax in 
response to chronic PP exposure. Juvenile European Sea bass was exposed to two 
selected antidepressants, (i) FLUX at the concentration of 0.5 µg/L and 50 µg/L, and 
(ii) VEN at the concentration of 0.01 µg/L and 1 µg/L. The chronic exposures were 
performed for 21 days, followed by a 7 day depuration period, to assess the 
reversibility of effects. Transcriptional levels of genes encoding for proteins involved in 
the neurotransmitter system, such as 5-ht3a and 5-ht3b, sert, mao, vmat and dopamine 
d2 and d3, were analyzed using qPCR-RT.  
Different profiles of mRNA expression levels were obtained after exposure to 
SSRI and SNRI. Exposure to FLUX resulted in an acute response at day 1 in all 
analyzed target genes, except for the monoamine degrading enzyme, mao, which was 
increased after 21 days. Exposure to VEN caused a significant differences at day 21 
for the receptor of serotonin 5-ht3a. For both serotonin receptors lower mRNA level 
were detected, but only for 5-ht3a with significant different. Dopamine d2 and d3 
receptors were significantly increased at 7 day of the recovery period.  
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These are important changes in the neuronal system of a marine fish species. 
The results suggest that antidepressants are able to modulate the expression of 
important neurotransmitter genes and receptors. We verified that genes from the 
analyzed genes in Sea bass had high degree of homology with D.rerio, O.latipes, 
T.rubripes, including H. sapiens and that all sequences clustered well within each 
corresponding group in a phylogenetic tree based on the multiple alignment analysis. 
Thus, we can assume that genes in D.labrax may have similar functions as in 
vertebrates. In humans, alterations of neurotransmitter genes and receptors are 
associated to human disorders as Alzheimer or Parkinson. For aquatic vertebrates, 
important functions include the regulation of anxiety, food intake, and aggression 
amongst others.  
The combined analysis of two classes of antidepressants on a marine fish 
species revealed substantial differences in the physiological response of 
neurotransmitter genes and receptor mRNA expression. Results should be considered 
in future risk assessments of pharmaceuticals disrupting the neuroendocrine system, 
which highlight the need of an individual evaluation of environmental compounds, even 
if similarities of effects could be assumed.  
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Resumo 
A depressão tem vindo a aumentar gradualmente ao longo destas últimas 
décadas, sendo que 1 em cada 10 indivíduos da União Europeia são afetados por esta 
doença. Os fármacos atualmente com maior número de prescrições médicas para o 
tratamento da depressão são o Prozac (fluoxetina), um potente inibidor seletivo da 
recaptação da serotonina (SSRI) e o Effexor (venlafaxina), inibidor da recaptação da 
serotonina e da norepinefrina (SNRI). As pesquisas mais recentes focam-se na 
preocupação destes fármacos serem reconhecidos como uma importante fonte de 
contaminação ambiental revelando que os alvos dos antidepressivos são conservados 
em termos evolutivos logo podendo impactar outros vertebrados. Como os 
neurotransmissores regulam uma grande variedade de sistemas fisiológicos desde 
mamíferos, peixes, moluscos e protozoários, espera-se que a presença dos 
psicofármacos possam afetar estes organismos a vários níveis, pois as principais 
propriedades terapêuticas destes fármacos são baseadas na modulação dos 
neurotransmissores.  
Neste trabalho avaliamos a transcrição de mRNA de genes do sistema 
serotonérgico e dopaminergico no cerebro do Dicentrarchus labrax através da técnica 
PCR em tempo real. Selecionou-se do sistema serotonérgico os genes: sert, 5-ht3A, 5-
ht3B; do sistema dopaminérgico: d2, d3; transportador não específico das monoaminas: 
vmat e por último uma enzima com atividade catalítica: mao. O Dicentrarchus labrax 
foi exposto a dois antidepressivos, (i) a fluoxetina com concentrações de exposição de 
0,5 µg/L e 50 µg/L, e (ii) a venlafaxina com concentrações de exposição de 0,01 µg/L e 
1 µg/L. As exposições crónicas foram realizados durante 21 dias, com um período de 
recuperação de 7 dias para avaliar a reversibilidade dos efeitos. Diferentes perfis de 
transcrição foram observados após a exposição a antidepressivos da classe SNRI e 
SSRI, (i) aumento da transcripção de todos os genes após exposição à fluoxetina (50 
µg/L) no primeiro dia demonstrando um efeito agudo, exceto a enzima degradadora, a 
mao. Esta apresentou não só um aumento agudo na expressão, mas também 
apresenta um efeito crónico na concentração mais elevada (50 µg/L); (ii) na exposição 
à venlafaxina o gene do sistema serotonérgico, 5-ht3A, mostrou diferenças 
significativas no dia 21 com indução nos níveis transicionais na concentração mais 
elevada (1 µg/L). No gene 5-ht3B verificou-se uma tendência de inibição crónica da sua 
expressão ao dia 21, contudo sem diferenças significativas. No sistema 
dopaminérgico, os genes do subtipo d2 e d3 após exposição do robalo à venlafaxina 
apresentaram aumento nos níveis de expressão no período de recuperação, na 
concentração mais elevada. Os antidepressivos partilham atividade farmacológica 
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comum, no entanto os nossos resultados demonstram que os SSRI e SNRI não 
partilham efeitos comuns nos genes que foram analisados, realçando um impacto 
adverso na expressão dos recetores do sistema de neurotransmissão. Sendo assim, 
os resultados apresentados fornecem novos desenvolvimentos sobre os efeitos 
crónicos dos antidepressivos quando em contacto com organismos marinhos não-
alvos indicando diferentes mecanismo de toxicidade. 
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OBJECTIVES 
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1.1. GENERAL INTRODUCTION  
Emerging contaminants, such as active pharmaceuticals have been detected in 
wastewater, streams and drinking water (Thomas et al., 2012) due to inadequacy of 
wastewater treatment methods combined with low environmental degradability of some 
compounds, and excretion of unchanged parent compound. The term “emerging” is 
applied to compounds present in the waters on which very little is known about the 
potential impact on the environment (Deblonde et al., 2011). Such chemicals are a 
worldwide concern, not only for the human health but also due to potential effects on 
non-target species and in general to ecosystems. These environmental 
pharmaceuticals have specific effects on neurological and physiological systems in 
fish, amphibians, birds and mammals  (Hampel et al., 2014; León-Olea et al., 2014), 
and their targets are highly conserved among vertebrates, and consequently aquatic 
animals, such as fish, are likely to be affected by environmental exposure (McGary et 
al., 2010). 
 In the last two decades, psychopharmaceuticals (PP), a huge group of 
pharmaceuticals, were recognized as an important source of environmental 
contamination. Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin 
Norepinephrine Reuptake Inhibitors (SNRIs) are the most common classes within the  
PP and are used to treat depression, anxiety, obsessive-compulsive disorders, and 
panic disorders (Silverstone, 2004).  
The main focus of this thesis was to evaluate transcriptional levels of genes in 
juvenile European Sea bass, Dicentrarchus labrax (D.labrax) (Linnaeus, 1758) brain in 
response to waterborne exposure to two PP, FLUX and VEN. Chapter 1 will provide 
insights into the main concepts addressed throughout this thesis in order to establish 
potential links between environmental exposures to PP and physiological and 
neurological changes in fish.  
 
 
1.2. Worldwide consumption of antidepressants 
 Over the past few years, PP are recognized as an important source of 
environmental contamination and increasing concern has emerged regarding their 
potential ecological impact, associated to a higher prevalence of psychiatric disorders 
leading to an increased number of prescriptions for PP worldwide (Silva et al., 2012). 
Portugal has a high prevalence of mental diseases which the main responsible is 
depression (Furtado, 2012). Portuguese National Authority for Medicine and Health 
Products (Infarmed) reported central nervous systems (CNS) pharmaceuticals on the 
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2nd rank of medicine sales, among these the PP (SSRIs and SNRIs) (Furtado, 2012). 
Worldwide SSRIs and SNRIs are among the most prescribed PP (Schultz and Furlong, 
2008), and reported increased consumption can be due to greater accessibility to 
drugs, prolonged use or the adoption of new therapeutic indications (Furtado, 2012). In 
2020, depression is expected be the world’s second most serious health disturbance 
(Lajeunesse et al., 2008).  According to the last Eurobarometer published in 2010, 10% 
of EU citizens took antidepressants to treat mental health disorders during 2009 
(Eurobarometer, 2010). The health data by the Organization for Economic Co-
operation and Development (OECD) from 2011 reported that the use of PP in Portugal 
is higher (71.9%) than the EU average (52.5%), (Silva et al., 2012), emphasizing the 
importance of this study.  
 Comparing European countries between 2000 and 2012, Portugal had an 
increased consumption of antidepressants, higher than in Italy and Norway, but similar 
to Denmark. In 2000, the substance with the highest consumption was FLUX; however, 
during 2000 to 2012 a marked increase was observed for other SSRIs, such as 
sertraline and escitolopram. In the case of SNRIs, such as VEN, a similar high growth 
was reported, although the impact is lower compared to sertraline and escitolopram  
(Furtado, 2012).   
 
1.3. Environmental presence of FLUX and VEN 
Detection of PP began in the late 1990’s and FLUX has been among the most 
ubiquitous pharmaceuticals found in environmental matrices (Schultz et al., 2011). 
FLUX is the PP with the most information available regarding behavior and 
physiological changes in aquatic animals, as well as data on the concentration in the 
environment as showed in Appendix I.  Briefly, environmental concentrations of FLUX 
were found from 0.012 in United Stated (Kolpin et al., 2002) to 0.93 µg/L in Steinheim, 
German (Christensen et al., 2009) in sewage treatment plant discharges (WWTPs) and 
VEN from the low ng/L level to as high as 2 µg/L in wastewater effluent in Denver. VEN 
was the predominant antidepressant observed in wastewater and river water samples 
in a report by Schultz and Furlong, (2008).  
Considering the presence of PP in aquatic ecosystems, the study of chronic 
effects of these PPs in aquatic species are needed to evaluate potential 
ecotoxicological risks, and to evaluate if aquatic organisms are affected by commonly 
observed, environmental concentrations.  
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1.4. Antidepressants profiles    
 
FLUX and VEN (Table 1) were both developed with the intention to alter the 
neurotransmitters biochemistry. Both compounds are polar, nonvolatile, non-
biodegradable and are resistant to hydrolysis and photolysis (Bendz et al., 2005). 
Schlüsener et al. (2015) reports that increasing UV radiation leads to photo-degradation of 
the contaminants. Consequently, antidepressants tend to escape sedimentation and 
biological treatment in WWTP. Half-life of VEN in natural river water was 2.1 days and 
19.2 h for their active metabolite Odesmethylvenlafaxine  (DVEN) (Schlüsener et al., 
2015); the half-life of FLUX is 1-3 days and their active metabolite norfluoxetine 
(NorFLUX) is 7-15 days (Airhart et al., 2007). FLUX and VEN are mainly biotransformed 
through N-demethylation by cytochrome P-450 isoenzymes CYP2D6 (Mandrioli et al., 
2006) in human liver, which results in the production of the active metabolite NorFLUX of 
FLUX (Hiemke and Härtter, 2000) and DVEN of VEN (Bisesi et al., 2014).  
Their persistence increases the possibility of bioaccumulation in aquatic or terrestrial 
organisms, because they are moderately to highly lipophilic (Halling-Sørensen et al., 
1998; Lajeunesse et al., 2011); they have by far the largest volume of distribution (up to 
100 L/kg body weight), indicating extensive tissue accumulation (Kreke and Dietrich, 
2008) and the compound octanol–water partition coefficient (Log Kow) values > 3 are of 
great concern indicating that they can be adsorbed in soils and living organisms (Table I). 
The greater the Log Kow of a compound, the more hydrophobic it is (Kreke and Dietrich, 
2008).  However, VEN was low or not observed (0.1 or 0.002 µg/kg) in brain tissue 
samples in wildlife fish (White sucker) sampled from two streams Creek in Colorado and 
Fourmile Creek in Iowa (Feito et al., 2013; Schultz et al., 2010). In fathead minnows when 
VEN and its metabolites were detected in tissues but did not accumulate to high 
concentrations (1.20 µg/kg) (Metcalfe et al., 2010). Thus, VEN levels in the neural tissue 
of fish suggested that this drug does not bioaccumulate during the exposure, although, as 
indicated above, the environment concentrations found were higher for VEN than FLUX 
antidepressant. In contrast with VEN, the FLUX antidepressant and it metabolite 
accumulated in the tissues (Kreke and Dietrich, 2008). Brooks and coworkers examined 
three different fish species, bluegill (Lepomis macrochirus), channel catfish (Ictalurus 
punctatus), and black crappie (Pomoxis nigromaculatus), from an effluent-dominated 
stream in northern Texas. In all three species, the highest concentrations of FLUX were 
detected in brain (1.58 ± 0.74 ng/g) and also in liver was detected FLUX (1.34 ± 0.65 
ng/g), and the lowest concentrations were detected in muscle tissue (0.11 ± 0.03 ng/g) 
(Brooks et al., 2005). In Japanese medaka (Oryzias latipes) exposed to FLUX NorFlux 
concentration in brain was 5 times greater than FLUX (Nakamura et al., 2008). While the 
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FLUX concentrations in aquatic systems are well below concentrations that produce 
lethality, as determined by LC50 values (0.55 mg/L in mosquitofish, Gambusia affinis, to 
1.6 mg/L in rainbow trout, Oncorhynchus mykiss), the bioconcentration of FLUX in the fish 
brain has raised concerns over potential sublethal effects on neuroendocrine modulation 
of physiological processes. These results document of antidepressants accumulated in 
aquatic organisms or uptake into brain tissue occurs from environmental exposure via 
water or food and/or bed sediment (Schultz et al., 2010). The lower observed 
concentrations of VEN in fish neural tissue may be explained in part by hydrophobicity, 
expressed by Kow. The log Kow of VEN is 3.28 which is lower than the reported than the log 
Kow for FLUX, which are 4.05 (Table 1) (Schultz et al., 2010). Thusly, some poorly soluble 
pharmaceuticals have the potential to bioaccumulate, thus enrichment through the food 
chain is possible (Crane et al., 2006).  
 
 
Table 1. Characteristics of FLUX and VEN  
Chemical 
characteristics 
FLUX VEN 
Structure 
 
 
CAS Number 54910-89-3 99300-78-4 
Molecular weight 
(g/mol) 
309.33 (Budavari, 2006) 277.4 (Budavari, 2006) 
Empirical formula C17H18F3NO (Budavari, 2006) C17H27NO2 (Budavari, 2006) 
log K
ow
 4.05  (Nentwig, 2007) 3.28 (Rúa-Gómez and 
Püttmann, 2012) 
Solubility in water 
(mg/g) 
38 (Nentwig, 2007) 270 (Rúa-Gómez and 
Püttmann, 2012) 
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1.5. Pharmacology of SSRIs and SNRIs 
The mechanisms of action of SSRIs and SNRIs are similar. SSRIs act in the 
serotonergic system of the central nervous systems (CNS) by inhibiting the reuptake of 
a serotonin by their carriers (serotonin transporter or sert) in the presynaptic 
membrane. Thereby increasing the concentration of serotonin in the synaptic clefts, 
increasing the serotonergic neurotransmission (Kreke and Dietrich, 2008; Valenti et al., 
2012). SNRIs act not only in serotonergic system, but in three neurotransmitters: 
serotonin, like SSRIs, norepinephrine and a somewhat weaker inhibition of dopamine 
(Fenli et al., 2013; Yamamoto and Vernier, 2011) and are approximately 10 times more 
potent at inhibiting serotonin uptake than norepinephrine (Celikyurt, 2012).  
The monoamine serotonin and the catecholamines, dopamine and 
norepinephrine, are concentrated and stored within localized vesicles in axons, 
dendrites and cell bodies (Golan et al., 2012). In vertebrates these neurotransmitters 
play essential roles in several physiological processes (Barros et al., 2012; Teyke et 
al., 1993). The storage process of neurotransmitters is performed by the vesicular 
monoamine transporter (vmat) – a non-specific monoamine transporter – that is 
released at the synapse following neuronal membrane depolarization. The serotonin, 
dopamine and norepinephrine from the synaptic cleft is than recycled by sert, 
dopamine transporter (DAT), norepinephrine transporter (NET) respectively, and this 
process represents the first important step in the of transmitter recycling. When the 
monoamines are not stored in presynaptic vesicles by vmat, they are degraded by 
monoamine oxidase (mao) enzymes located in the outer mitochondrial membrane 
(Maximino, 2012). The mao is present in two isoforms in mammals, mao a and mao b, 
with the first having higher affinity for serotonin (Johnson, 1968). After the release of 
monoamines to the synaptic cleft, the activation of receptors occurs postsynaptically, 
and the neurons opens ligand gated ion channels (5-ht3), which regulate the action 
potential, and therefore, the signal transmission in neurons (Bisesi, 2014).  
 
1.5.1. Monoamine serotonin 
The monoamine serotonin or 5-Hydroxytryptamine is a neurotransmitter with a wide 
range of functions that is found in both the central and peripheral nervous systems 
(Jain, 2002). It was initially isolated and identified by Rapport and colleagues in 1948 
(Mennigen et al., 2011; Rapport et al., 1948). It is now known to exist in nearly every 
biological organism, including plants, invertebrates and vertebrates, which indicate an 
evolutionarily ancient origin. For curiosity, this neurons system of the mammalian brain 
comprise the most extensive and complex neurochemical network in the CNS after that 
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of glutamate, which makes up the basic wiring of the brain. It has been estimated that 
the human brain contains about 250 000 serotonin neurons of a total of 1011 neurons 
(Artigas, 2012). In vertebrates, high concentrations of serotonin are found in the brain, 
gut, kidney and lung (Kreke and Dietrich, 2008; Mennigen et al., 2011). Furthermore, 
serotonin is present in the serum, and has effects on smooth muscle contraction (Kahn 
et al., 1992). The majority of monoamine serotonin is found in the gut, where it 
modulates motility and initiates peristaltic and secretory reflexes (Gershon, 2003).  
Serotonergic projections exist from the raphe nuclei to almost every part of the 
vertebrates brain; areas as thalamus and cortex (Howe et al., 2013; Larson et al., 
2014). In mammal’s brain, serotonin is a key neurotransmitter that modulates normal 
physiology including sleep, food intake, stress (Larson and Summers, 2001), appetite, 
the immune system, reproduction, behavior (Brooks et al., 2003) and sexual behavior 
(Lucki, 1998). Serotonin has the same function in vertebrates, including the regulation 
of locomotion, mood control (Veenstra-VanderWeele et al., 2000), feeding (Larson and 
Summers, 2001), brain development (Cornide-Petronio et al., 2015; Daubert and 
Condron, 2010), energy metabolism (which depends on complex interaction between 
many physiological and environmental factors) (Pérez Maceira et al., 2014) and 
aggression (Huber et al., 1997; Larson and Summers, 2001; Raleigh et al., 1991), such 
as FLUX, have been found to inhibit food intake (Pérez Maceira et al., 2014).  
In chemical terms, this neurotransmitter is a hydrophilic indole amine derived from 
the amino acid tryptophan. The key enzyme for serotonin synthesis is the tryptophan 
hydroxylase (TPH), present in the brain mostly in its second isoform, TPH2, which 
converts tryptophan to 5-hydroxytryptophan (5-HTP), a process limited by tryptophan 
availability (Maximino, 2012). 5-HTP is than conversed in serotonin by the aromatic L-
amino acid decarboxylase (AADC). Both enzymes are located in the cytoplasm of 
serotonergic neurons in both the cell body and the cellular processes. The principal 
enzyme in monoamine degradation is MAO, the oxidative deamination of serotonin by 
converting it into 5-hydroxy-3-indolacetaldehyde (5-HIAL), which is further metabolized 
into 5-hydroxy-3-indolacetic acid (5-HIAA) by aldehyde dehydrogenase type 2 (ALDH2) 
(Pytliak et al., 2011).  
  
1.6. Catecholamine: Dopamine and Norepinephrine  
Dopamine and norepinephrine belongs to the family of neurotransmitter 
catecholamine and are widely distributed in mammalian species and vertebrates. 
Dopamine constitutes about 80% of the catecholamine content in the brain (Vallone et 
al., 2000). Dopamine and norepinephrine act as modulator of neuronal activity 
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regulating many different functions in CNS (Callier et al., 2003; Park et al., 2006). 
Vertebrates (Cooper et al., 2003) and mollusks (Lacoste et al., 2001) release 
norepinephrine during acute stress in response to danger (Adamo, 2008; Wingfield, 
2003). The release of norepinephrine during acute stress and their responses prepare 
the animal to physiological changes that can influence their immune function (Adamo, 
2008). Dopamine exerts its physiological systems or organs by binding to multiple 
membrane receptors couple to heterotrimeric G proteins (GPCR) (Callier et al., 2003). 
It is described to be involved in the modulation of a number of key cerebral functions, 
as sensory perception, learning and memory, hormonal regulation and control of body 
temperature among others (Blackstone, 2009; Yamamoto and Vernier, 2011). Similar 
to serotonin, dopamine controls food intake and sexual behavior (Callier et al., 2003). 
Central dopaminergic neurons originate, for the most part, in different areas of the brain 
and have different projections.  
Catecholamines are amine derivatives of catechol (2-hydroxyphenol) (Yamamoto 
and Vernier, 2011).synthesized from L-3,4-dihydroxyphenylalanine (L-dopa) by the 
action of aromatic amino acid decarboxylase (AADC), which is produced from tyrosine 
by tyrosine 3-monooxygenase or tyrosine hydroxylase (TH). Following, dopamine is 
further processed in norepinephrine by dopamine ß-hydroxylase and subsequently in 
epinephrine (or adrenaline) by phenylethanolamine N-methyltransferase (Golan et al., 
2012).   
 
1.6.1. Biogenic amine receptors 
 Serotonin receptors are divided into seven different families (5-ht1, 5-ht2, 5-ht3, 5-
ht4, 5-ht5, 5-ht6 and 5-ht7) (Hoyer et al., 2002) based on the receptor structure, their 
affinity for different ligands and activation of the secondary messenger (Chegini et al., 
2014). In teleost fish, serotonin receptors have been identified and characterized in 
several species such as zebrafish (Danio rerio), European flounder (Platichthys flesus), 
Gulf toadfish (Opsanus beta), and Puffer fish (Yamaguchi and Brenner, 1997; Lu et al., 
2007; Best and Alderton, 2008; Mager et al., 2012). Serotonin receptors comprise 
multiple subunits, and the G-protein coupled (metabotropic receptors) signaling 
pathways  are of the Gs, Gq and Gi sub-types, with the exception of the 5-ht3 receptor 
that are ligand-gated ion channels (ionotropic) (Pytliak et al., 2011). The 5-ht3 receptor 
directly gates an ion channel inducing rapid depolarization and consequently the 
release of neurotransmitters (Artigas, 2012; Kondaurova et al., 2012). This ion channel 
receptor are members of the Cys-loop superfamily with relatively conserved trans 
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membrane domains (Descarries and Riad, 2012), and comprises two subunits known 
as 5-ht3a and 5-ht3b cloned in Human (Chameau and Van Hooft, 2006). Until now, five 
dopamine receptors proteins were isolated in vertebrates encoded by different genes. 
Along the years, there was a strong interest for dopamine receptors due to the 
alteration in dopamine transmission in a few human pathologies, essentially 
Parkinson’s disease, addiction to drugs of abuse, as cocaine, or disorders of mood and 
schizophrenia (Callier et al., 2003). In vertebrates different receptors mediate 
dopamine signaling, D1–D5. These receptors are grouped into two classes (D1-like and 
D2-like) dependent on the G-protein to which they couple, the basis of their differences 
in biochemical and pharmacological properties. The presynaptic dopamine receptor, 
most of which belongs to the class D2 (D2, D3 and D4), act as auto receptors. These 
auto receptors perceive excessive flow of dopamine from the synapse and reduce the 
dopaminergic tone, reducing the dopamine synthesis in the presynaptic neuron and 
reducing neuronal discharge rate and the release of dopamine (Callier et al., 2003).  
 
1.7. European seabass (Dicentrarchus labrax): marine fish in study 
European seabass belongs to the order of Perciformes, family Moronidae 
(Vázquez and Muñoz-Cueto, 2015), and is a gonochoristic marine teleost fish (Louro et 
al., 2014). European seabass is an important popular cultured specie with a high 
economic value (Santos et al., 2010). In Europe, the consumption of Sea bass and 
production demand has increased over the past 15 years (Fuentes et al., 2010), and 
nowadays is the fourth most produced fish in European aquaculture (Tine et al., 2014).  
For this reason, its production was expanded along the Mediterranean coast, and Sea 
bass became one of the main cultured fish species (Fuentes et al., 2010). Due to high 
capture pressure, future conservation and management issues were raised (Tine et al., 
2014). The specie is distributed along the northeast coast of the Atlantic Ocean, from 
Norway to Senegal and from Mediterranean to Black Sea (Kottelat and Freyhof, 2007; 
Vázquez and Muñoz-Cueto, 2015), being also found throughout the Portuguese coast 
(Vasconcelos et al., 2009).  
Due to accumulation of contaminants in several tissue, including in muscle, the 
marine fish can be a vehicle for human exposure to compounds (Fent et al., 2006; 
Kreke and Dietrich, 2008; Lajeunesse et al., 2011; Reis-Henriques et al., 2009). Also, 
D. labrax are carnivorous, feeding on fish, crustaceans and cephalopods(Pickett and 
Pawson, 1994)(Pickett and Pawson, 1994) and, may accumulate organic pollutants 
through its food (Dural et al., 2007; Türkmen et al., 2005). Moreover, the European Sea 
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bass is described has a good bioindicator organism reflecting the local water 
environmental pollution in their tissues (Schnitzler et al., 2011).  
This marine species is a euryhaline fish tolerating a range of salinities (0-60 psu) 
(Tine et al., 2014). Most studies with aquatic organisms exposure to contaminants is 
based on freshwater species (Bisesi et al., 2014; Brooks, 2014; Brooks et al., 2003; 
Kreke and Dietrich, 2008; Metcalfe et al., 2010). So, it is essential to analyze the 
effects in a marine fish species, which have striking differences in their physiology (e.g. 
osmoregulation). In 2014 with seabass genome published it was proven that the 
European Sea bass genome has the highest number of gene copies linked to ion and 
water regulation, with 94 genes, among fully sequenced teleost (Tine et al., 2014).  
A decade ago, few fish genomes were available Fugu rubripes (Aparicio et al., 
2002), Tetraodon nigroviridis (Jaillon et al., 2004), Danio rerio (Howe et al., 2013), 
Oryzias latipes (Kasahara et al., 2007) and Gasterosteus aculeatus (Jones et al., 
2012). The European Sea bass moved in the last 10 years to the forefront of availability 
of genetic and genomic resources (Louro et al., 2014), and since 2014 the genome is 
publically available (http://Sea bass.mpipz.mpg.de, Tine et al., 2015). Hence, the 
species is a good experimental model for ecotoxicological assays, due to their 
important role in their ecosystems, wide geophraphical distribution, availability through 
aquaculture production and the good response in behavioral terms when exposed to 
pollutants (Almeida et al., 2010). European Sea bass also constitutes an important 
model for many basic research areas, including population genetics (Bahri-Sfar et al., 
2000), feeding activity (Sánchez-Vázquez et al., 1998), response to salinity (Boutet et 
al., 2006; Nebel et al., 2005). However, there is a need for more information on 
contaminant levels in European fish and on chronic effects due to exposure to 
emerging pollutants. 
 
1.8. Overview of the effects of antidepressants  
The scarcity of information about the fate and the long-term effects of PP and 
their active metabolites in aquatic species makes risk assessment difficult (Lajeunesse 
et al., 2011). Futhermore, the impacts and ecotoxicological potencial of neuroactive 
drugs on aquatic organisms and communities are important to assess (Bendz et al., 
2005), but are still not well understood or described (Kreke and Dietrich, 2008; 
Lajeunesse et al., 2011).  
There are four important reviews (Brooks et al., 2003; Kreke and Dietrich, 2008; 
Menningen, 2011; Oakes et al., 2010) and a more recent serotonin review (Prasad et 
al., 2015) that provide several antidepressants-induced neuroendocrine disruption in 
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teleost fish, for example in reproduction and endocrine functions, control of feeding, 
fish stress, behaviors and immune system. In the reproduction and endocrine function 
in teleost fish, the monoamine serotonin can affect gonadotropin-releasing hormone 
(GnRH) regulated gonadotropin release from the pituitary (Khan and Thomas, 1994). 
So, the regulation of reproduction by hypothalamo-pituitary-gonadal (HPG) axis and it 
is stimulated by GnRH, which act to stimulate the release of luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) from the pituitary (Prasad et al., 2015), both of 
which can regulate key genes involved in reproductive physiology including sex 
hormone synthesis, oogenesis, and vitellogenesis (Khan and Thomas, 1994).  
Through modulation of neurotransmitter systems by exogenous compounds, 
reproductive fitness can be altered via effects on behavior and physiology. PP altered 
the predator avoidance behavioral phenotype of juvenile fathead minnows (Thomas et 
al., 2012) due to alterations in brain function that impair predator avoidance behavior 
caused by changes in neurotransmitter levels in the brain. In most vertebrate species 
examined so far, increased serotonergic activity has been associated with an inhibition 
of aggressive behavior (Kreke and Dietrich, 2008). Behavioural effects of FLUX and 
VEN has been observed in larval fathead minnows and hybrid striped bass including a 
reduction of the escape response, a measure of predator avoidance (Yamaguchi and 
Brenner, 1997).  
It has long been recognized that stress affects the immune response in mammals 
(Kreke and Dietrich, 2008). An investigation reported that serotonin may play a role as 
modulator of the immune response in fish and that SSRI may mimic 
immunomodulatory effects. It has been shown that isolated lymphocytes cells from 
rainbow trout (Oncorhynchus mykiss) may express a functional SERT that can be 
blocked by SSRIs, thereby inhibiting serotonin uptake into the cells (Ferriere et al., 
1999).  
 
  
1.9. Objectives 
The general aim of this master thesis was to evaluate transcriptional levels of 
genes in a marine fish species, the D. labrax, in central nervous system in response to 
waterborne exposure to two PP. Firstly, selected target genes of the European Sea 
bass were identified and characterized from the neurotransmitter system in the brain. 
Secondly, European Sea bass was chronically exposed to two selected 
antidepressants and chronic effects were analyzed by qPCR-RT on the transcriptional 
patterns of neurotransmitter genes from the brain.   
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In detail the objectives of this study were:  
(i) To identify selected target genes of the European seabass from the 
neurotransmitter system in the brain. To compare selected target 
sequences of European Sea bass to sequences of other species Oryzias 
latipes, Takifugu rubripes, Homo sapiens and Danio rerio, by multiple 
alignments, and phylogenetic trees. 
(ii) To design and evaluate real-time PCR assays for genes of interest, such as 
5-Hydroxytryptamine subtype 5-ht3a and 5-ht3b, serotonin transporter 
receptor (sert), monoamine oxidase (mao), vesicular monoamine 
transporter (vmat) and dopamine d2 and dopamine d3;  
(iii) To analyze effects on the gene expression in European Sea bass 
chronically exposed to two selected antidepressants, FLUX (SSRI) and 
VEN (SNRI).  
The selected targets for the gene expression analysis were based on the 
following rationale: (i) The serotonin and dopamine receptor subtypes are important, 
because the monoaminergic system of the CNS is generally well conserved in 
vertebrates, and monoamines and catecholamines are implicated in the regulation of 
feeding, growth, reproductive fitness and others; (ii) The monoamine oxidase controls 
the degradation of monoamines in presynaptic cleft; (iii) The neurotransmitter 
transporters (sert or dat) represent the main targets for the pharmacological action of 
SSRIs or SNRIs. These transporters are located in the presynaptic plasma membrane 
and are primarily responsible for the synaptic clearance of serotonin or dopamine after 
neurotransmitter release.  
Overall, the presented findings contribute to the study of chronic exposure effects 
of PP on a marine fish species, which may be used as a sentinel species in estuaries 
or coastal regions.  
 
 
1.10. Thesis structure 
This thesis is organized in three chapters: the first includes a general introduction 
to the topic under investigation, and to the objectives of the study. The second chapter 
follows in general the structure of a research paper including a brief introduction, 
material and methods, results, discussion, and conclusions. The third and final chapter 
includes a general discussion, the final conclusions and references. 
 
  
 
 
 
 
 
Chapter 2 
 
TRANSCRIPTIONAL LEVEL OF GENES INVOLVED IN THE 
NEUROTRANSMITTER SYSTEM OF DICENTRARCHUS LABRAX 
IN RESPONSE TO CHRONIC EXPOSURE TO 
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Transcriptional level of genes involved in the neurotransmitter 
system of Dicentrarchus labrax in response to chronic 
exposure to psychopharmaceuticals 
 Abstract 
Up to 10% of the human population suffers from depression. SSRIs and SNRIs 
are prescribed for clinical depression and detected in aquatic ecosystems. The main 
aim of this study was to explore and evaluate transcriptional levels of neurotransmitter 
genes in brain of a marine fish species European sea bass. The juveniles were 
exposed to two PP: (i) FLUX at the concentration of 0.5 µg/L and 50 µg/L; (ii) VEN at 
the concentration of 0.01 µg/L and 1 µg/L. The chronic exposures were performed for 
21 days, and followed by a 7 day of recovery period to assess the reversibility of 
effects. Transcription levels of genes encoding for proteins involved in the 
neurotransmitter system, such as 5-ht3a and 5-ht3b, sert, mao, vmat and dopamine d2 
and d3 were analyzed using qPCR-RT.  
One of the main results was that both antidepressants act differentially on the 
neurotransmitters gene expression. We found strong and unique profile of effects in 
transcription levels in FLUX and VEN. The FLUX exposure revealed acute induction on 
day 1 in all targets genes, except mao, where a chronic effect was present at day 21. In 
contrast to FLUX, VEN exposure at day 21 decreased the mRNA expression of the 
receptors of serotonin 5-ht3a and 5-ht3b, but only for 5-ht3a with significant differences. In 
addition, VEN exposure increased Dopamine d2 and d3 receptor mRNA expression at 
the recovery period at day 28.  
Analyzed dopaminergic and serotonergic neurotransmission genes from 
European Sea bass had a high degree of homology with D.rerio, O.latipes, T.rubripes, 
and H. sapiens, analyzed by multiple alignments and phylogenetic trees. Sequence 
similarities indicate the possibility of similar gene functions in vertebrates. Modulated 
genes from this study, are associated in humans with several mental disorders, and are 
known to control various behavior and food intake in aquatic vertebrates. These results 
provide new insights into the chronic effects of psychopharmaceutical compounds and 
indicate different mechanism of toxicity.  
 
Keywords: Fluoxetine; Venlafaxine; European seabass; qPCR-RT; serotonin receptors; 
dopamine receptors; neurotransmission; neurotransmitters 
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2.1. INTRODUCTION 
Since the ﬁrst detection of pharmaceuticals in sewage water efﬂuents in the mid-
1970s, there have been numerous reports on the presence of these substances and 
their metabolites in surface waters on a global scale (Grabicova et al., 2014a). The 
wide distribution of these substances in the environment has become a high priority for 
regulatory agencies involved in human and ecological risk assessment (Park et al., 
2012). The biological activity of some pharmaceuticals indicates that they can have 
physiological effects on non-target organisms at environmental relevant concentrations 
(Brooks et al., 2003; Lajeunesse et al., 2011; Mennigen et al., 2011). Within the 
pharmaceuticals a major group exists – in terms of medicine sales and increasing 
consumption – where scarce information is available, the PP (Santos et al., 2010). This 
group includes monoamine reuptake inhibitors, e.g. selective serotonin reuptake 
inhibitors (SSRIs), such as fluoxetine (FLUX), and serotonin and norepinephrine 
reuptake inhibitors (SNRIs), such as venlafaxine (VEN) (Grabicova et al., 2014b). It has 
long been understood that neurotransmitters, especially monoamines, play a major role 
in modulation of behavior, as well as many physiological functions in humans. 
Serotonin and dopamine are two of the major players of the neurotransmitter system 
(Gardner et al., 2008). Serotonin has a critical role in the regulation of temperature, 
behavior, appetite, sleep and mood control. Dopamine has been implicated in the 
control of motoric function and emotional behavior (Schultz, 2002). Whereas 
norepinephrine is thought to be involved in behavioral arousal, as well as playing a 
major role in fight or flight response (Harley, 2004). The mechanisms of action of 
SSRIs (e.g FLUX) and SNRIs (e.g VEN) are similar: SSRIs act on the serotonergic 
system of the CNS by inhibiting the reuptake of serotonin by their carriers (SERT) in 
the presynaptic membrane, thereby increasing the concentration of serotonin in the 
synaptic clefts and increasing serotonergic neurotransmission (Kreke and Dietrich, 
2008; Valenti et al., 2012); SNRIs act not only on the serotonergic system, but on three 
neurotransmitters: serotonin, norepinephrine and a weaker inhibition of dopamine 
(Fenli et al., 2013; Yamamoto and Vernier, 2011). Because monoamines directly 
modulates some cellular functions and acts on the CNS in many organisms (Kreke and 
Dietrich, 2008), manipulations of monoamines levels can influence diverse 
physiological processes, as reproduction, development, behavior and neuroendocrine 
signaling pathways (Brooks et al., 2003; Foran et al., 2004; Kreke and Dietrich, 2008; 
Mennigen et al., 2011; Oakes et al., 2010). Previous studies indicate that aquatic 
species exhibit abnormal behavior and lower levels of anxiety when they are 
chronically exposed to SSRIs impeding fitness and survival on a population scale 
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(Almeida et al., 2012; Bisesi et al., 2014; Brooks et al., 2003; Kreke and Dietrich, 2008; 
Weinberger and Klaper, 2014). Generally a high level of serotonin activity is associated 
with low levels of aggression, apprehensive and/or subordinate behavior. In contrast, 
individuals with low serotonin function tend to be more aggressive, bold and/or have a 
dominant position and an increased time to capture prey (Oakes et al., 2010). 
Although, the question of how gene expression is perturbed in the brain by 
antidepressants exposure is not yet explained. The gene expression analysis in aquatic 
species can elucidate the alterations of transcription levels, detect effects of 
contaminants on biochemical pathways, and be used for comparison of gene 
expression proﬁles to determine differences/similarities in responses of several 
organisms (Park et al., 2012; Rogers et al., 2011). There are no studies comparing 
effects of different classes of pharmaceuticals, as SSRIs and SNRIs on global gene 
expression in aquatic organism.  
The main focus of this study was to evaluate transcriptional levels of genes in 
juvenile European seabass brain in response to waterborne exposure to two PP, FLUX 
and VEN. Two different concentrations were chosen, one orientated to frequently 
observe environmental level, and the other to rather physiological relevant level (100x 
higher than environmental level). To answer the question whether PPs act differentially 
on the neurotransmitters, transcription levels were measured in brain by quantitative 
real-time qPCR-RT. Since the major focus of previous works was on freshwater 
species, in this work we have chosen a marine fish species, one first study with a 
marine organism, which have striking differences in their physiology (e.g. 
osmoregulation) (Tine et al., 2014). A wide geographic distribution over Europe and is 
explored as a sentinel species for environmental field studies covering estuaries and 
marine coastlines. Moreover, Sea bass is an important cultured species with economic 
value, and changes in aggression or feeding behavior can have a negative impact in 
aquaculture production in estuaries. We discuss these findings in the context of 
transcription of levels in neurotransmitters in qPCR-RT because FLUX and VEN has 
been detected in the environment.  The environmental relevance of PP exposure and 
their chronic effects on D.labrax were analyzed and will be helpful in designing 
methodologies for future risk assessments of pharmaceuticals that target the 
neuroendocrine system.  
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2.2. MATERIAL AND METHODS 
2.2.1. Fish maintenance 
Juvenile European Sea bass were obtained from a commercial aquaculture 
(Aquanord, Gravelines, Nord, France), and kept at the Aquatic Animal Facility of 
CIIMAR – Interdisciplinary Centre of Marine and Environmental Research (Portugal, 
Porto). Fish were acclimated for at least 1 month before the beginning of the 
experiments. Animals were kept in tank with 2000 L; they were fed every day and kept 
under natural conditions of temperature (13.5 ºC-16.5 ºC) and range of salinities (22.4 - 
25.7 psu). In our facilities, we kept Sea bass at pH between 5.78-6 in tanks with 
artificial reconstituted seawater. Levels of ammonia and nitrite were checked daily and 
maintained below 0.5 mg/ml, with value range 0.02 - 0.04 and 0.06 - 0.07, respectively.  
 
2.2.2. Fish condition and exposure  
The European Sea bass was exposed to two antidepressants FLUX and VEN in 
a flow-through system in two different experiments. Two concentrations were chosen 
for each PP: 0.5 µg/L and 50 µg/L for FLUX, 0.01 µg/L and 1 µg/L for VEN. After the 
acclimation period, the European seabass was exposed in 12 tanks with 61 L each, 
with a water daily replacement of 70%. For each treatment, 3 replicates of the following 
groups control; solvent control group (dimethyl sulfoxide – DMSO 0.008%); FLUX with 
0.5 µg/L and 50 µg/L. In the experiment with VEN, the same experimental setup was 
used, three replicates per group control; solvent control group (DMSO) with 
concentration 0.01%; VEN at 0.01 µg/L, and 1 µg/L. A total of 288 animals were used 
for the exposure experiment with FLUX, and 144 seabass for the exposure experiment 
with VEN; animals were randomly distributed in the aquariums (24 animals in each 
aquarium in the FLUX experiment, and 12 animals per aquarium in the VEN 
experiment). The exposure lasted for 21 days (chronic exposure) and followed by a 7 
day period of recovery (no compound or DMSO added) (Appendix II). The animals 
were fed during the experiments every 2 days. 
 
2.2.3. Tissue sampling 
 Biological sampling was performed at day 1 and day 21 of exposure, and at day 
28 after the recovery period (Fig. 1). For tissue sampling, animals were anesthetized in 
MS222 (0.25%).  Before dissection, seabass was weighed and measured (total and 
standard) and the cranial region was dissected. The total brain were excised from the 
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head, placed in RNA Later at 4 ºC overnight and stored at -80 ºC until further use for 
gene expression analysis.  
 
 
2.2.4. Design of primers 
2.2.4.1. Database construction and annotation  
Primer pairs for real-time PCR for 5-Hydroxytryptamine subtype 3A and 3B (5-
HT3A and 5-HT3B), serotonin transporter receptor (sert), monoamine oxidase (MAO), 
vesicular monoamine transporter (vmat) and dopamine d2 and d3 (Table 2) were 
designed based on the genome sequences of European seabass, which was recently 
published by Tine, 2014 (Tine et al., 2014), available at the UCSC Genome Browser at 
http://Sea bass.mpipz.mpg.de/cgi-bin/hgGateway.  
After obtain the Sea bass mRNA sequences, we compared them to the DNA 
sequences. Using the comparison to DNA sequences, specific primers were designed 
that were spanning an intron, such that primers were located on different exons 
(Appendix IV). For primer design we used the software PRIMER 3 Plus Primer 
(http://www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi/).  
Important parameters for the design of primers are the annealing temperature, % 
GC (50%) and the localization of the primer – influencing their efficiency. The 
oligonucleotides were purchased from Stabvida (Portugal). 
 
Fig. 1. Scheme chronological dissection of tissues. Animals were added to the aquarium for 
acclimatization. At day 0 the experiment started by addition of the compounds. At day 1 (one day 
after adding the compounds) we did the first sampling. The last 7 days no release contaminants or 
DMSO. 
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Fig. 2. Electrophoresis on agarose gel (1.5%) 
corresponding bands of the 28S and 18S juvebile Sea bass 
brain in brain RNA samples    
 
2.2.5. RNA extraction and agarose gel electrophoresis and quantification  
 Total RNA was isolated from approximately 30 mg of tissue samples using the 
RNAspin Mini Kit (GE Healthcare, Hilden, Germany) following the manufacturer’s 
instructions. RNA quality was checked by gel electrophoresis on a 1.5% agarose gel 
(NZYtech genes and enzymes, Lisbon, Portugal). In the extracted RNA of brain 
samples from Sea bass, two major bands were verified corresponding to the 18S and 
28S subunits (Fig.2). RNA concentration was determined using a UV-Vis 
spectrophotometer measuring the 260/280 ratio, Take3™ Multi-Volume Plate (Biotek, 
Taiwan) and the plates with volume 2 µl (Biotek, Taiwan). Total RNA was extracted and 
verifying the integrity and quality of RNA in agarose gel bands. Following, 1 μg of total 
RNA was subjected to digestion of genomic DNA using Deoxyribonuclease I, 
Amplification Grade (Invitrogen). In Appendix VI shows the difference of RNA quality. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.6. cDNA synthesis and Polymerase chain reaction (PCR) 
cDNA was synthesized using the iScript cDNA Synthesis Kit from BioRad. To 
confirm the sequences identities, PCR was performed in a Biometra Thermocycler with 
1 µl of cDNA, 0.2 mM of DNTPs, 0.4 µM of each primer and 2.5 mM of MgCl2 in a total 
volume of 25 µl, using Taq DNA Polymerase (BioRad, EUA). The protocol was 
performed using the following conditions: 2 minutes denaturation at 94 ºC, 30 second 
denaturation at 94 ºC, 30 seconds annealing at 55 ºC, and 20 seconds at 72 ºC of 
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extending the polymerization reaction, for 35 cycles, followed by 2 minutes of a final 
extension at 72 ºC.  
2.2.7. Electrophoresis agarose gel, DNA isolation, cloning and sequence 
analysis 
PCR products were separated by gel electrophoresis on a 1.5% agarose gel in 
Tris-acetate-EDTA buffer – TAE buffer stained with 6x GelRedTM Nucleic Acid (Biotium) 
and the PCR products were visualized under UV light. The bands of expected size 
were cut out carefully and eluted from the gel according to manufacturer´s protocol, 
using the commercial Gel Band Purification Kit, GE Healthcare. It was observed with 
high resolution gel electrophoresis and resulted in a single product with length 109bp 
sequence similar to SERT, a 91bp sequence similar to 5-HT3B, a 186bp sequence 
similar to 5-HT3A, a 88bp sequence similar to D3, a 121bp sequence similar to D2, a 
86bp sequence similar to VMAT and a 100bp sequence similar to MAO were identified 
(Appendix III).  
The isolated fragments were then inserted in pGEM plasmid vector (pGEM® - T 
Easy Vector Systems – Promega) and incorporated in E. coli using Blue Competent 
Cells (Novagen). Bacteria were grown overnight for 16-24 hours in solid medium (40g/L 
LB Agar (nzytech), ampycilin 100 µg/ml, Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
0.5 mM and X-Gal 40µg/ml) at 37 ºC. The correct colonies were isolated (white 
colonies) from solid medium and incorporated in 5 ml Liquid medium LB Broth (20g/L, 
Sigma) and cultured overnight at 37 ºC with shaking. After, the plasmids were isolated 
using the Wizard Plus SV Minipreps DNA Purification System (Promega). The inserts 
were sent to STABVIDA (Portugal) for sequencing. The identities of all sequences were 
checked using the Basic Local Alignment Search Tool (Blast) at National Center for 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov), after using the 
Vecsreen (http://www.ncbi.nlm.nih.gov/tools/vecscreen) to identifying segments of a 
nucleic acid sequence that may be of vector origin. The alignments of the obtained 
sequences with other mammal and fish species was conducted with ClustalW Multiple 
Alignment (http://www.ebi.ac.uk/Tools/msa/clustalo/).  
Phylogenetic trees were performed with the free software Mega 6.06 
(http://www.megasoftware.net/). Phylogenetic analysis was done using the neighbor-
joining method and a percentage of concordance based on 1000 bootstrap iterations. 
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2.2.8. Real-Time quantitative qPCR-RT   
Gene expression quantification of SERT (002060), 5HT3A (00148200), 5HT3B 
(00046560), D2 (00129960), D3 (00076420), MAO (00054530), VMAT (00018080) was 
performed in brain from Sea bass by means of quantitative real-time reverse 
transcriptase PCR (qPCR-RT). Elongation factor 1 (EF1), 18S ribosomal RNA (18S 
rRNA), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and ribosomal 
protein L17 gene (L17) were evaluated as possible reference genes. 
For qPCR-RT, 1 µg of total RNA was subjected to digestion of genomic DNA 
using DNAse I and first strand cDNA was synthesized using iScript cDNA Synthesis Kit 
from Biorad. Optimal primers concentrations were determined after evaluation of the 
highest fluorescence signal at lower Ct number. The concentrations tested were 600 
nM, 300 nM, 150nM and 50nM; finally 300 nM was selected for the amplification of 
target and housekeeping genes. Real-time PCR amplification was done in an 
Eppendorf Realplex 4, with the plates calibrated with iCycle IQ® PCR plates. Also, use 
IQSybr Green Supermix (Bio Rad), with 10 μl SYBR Green mix, 2 μl of each primer 
(final concentration of 300 nM) and 1 μl of cDNA in a total volume of 20 μl. Reactions 
were conducted under the following conditions: 95 ºC for 3 minutes, followed by 40 
cycles at 95 ºC for 10 seconds, 54 ºC for 30 seconds and 72 ºC for 30 seconds. At the 
end of each run, a melting curve analysis was done (from 55 ºC to 95 ºC) to determine 
the formation of specific products. Samples were run in technical duplicates. Controls 
(no template added) were run to exclude contamination and the formation of primer 
dimers. To determine the efficiency of the PCR reactions, standard curves were made 
for all the genes, with 6 serial dilutions of the template (concentrations range from 0.05 
to 50 ng/μl), and the slopes and regression curves were calculated. Quantification of 
the mRNA expression of the genes were normalized with a multiple reference gene 
approach as detailed in 2.1.10.  
Melting curve analysis was performed which resulted in single product specific 
melting temperatures. No primer-dimers were generated during the applied 40 real-
time RT-PCR amplification cycles and in control of No Template Control (NTC) were 
not identified expression samples.  
 
2.2.9. Confirmation of primer specificity and Real-time PCR amplification 
efficiencies 
Real-time RT-PCR efficiencies were calculated from the given in real-time RT-
PCR software. Although, to confirm the software efficiency  it was calculated according 
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to the equation: E=10(-1/slope) (Table 2; Fig.3) and threshold was defined for all genes at 
100 units of fluorescence intensity.  
2.2.10. Normalization of reference genes  
The most commonly used normalization strategy for quantitative real-time qPCR-
RT, involves standardization to a constitutively expressed control gene. The 
normalization is necessary in all experimental conditions. No single gene is 
constitutively expressed in all cell types implying that the expression stability of the 
intended control genes has to be verified before each experiment (Andersen et al., 
2004). The expression of the target genes (sert, 5-ht3a and 5-ht3b, dopamine d2 and d3, 
mao and vmat) was normalized to the mRNA expression of multiple reference gene 
apllying the Normfinder (Andersen et al., 2004). In the case of Normfinder, the software 
calculates the average expression stability between four selected potential reference 
genes (GAPDH, L17, EF1, 18s). The best combination of two reference genes was 
selected (Fig.4), which was the combination of 18S + EF1 (stability value: 0.654) in our 
exposure experiments to FLUX and VEN. The intergroup variations plotted with the 
intragroup variation as error bars (Fig. 4) is given an overview of the obtained 
expression stability for all analyzed reference genes as calculated by NormFinder. For 
the software program (Normfinder), all samples from the corresponding treatment 
groups and sampling dates used to construct normalization factors. As observed in Fig. 
4 opposite orientations for the intergroup variations were chosen as recommended. For 
normalization the geometrical mean of 18S and EF1 was used and calculated for each 
Fig. 3. Real-time RT-PCR SYBR Green fluorescence of 5-ht3b gene with: a) efficiency curve, slope value and threshold 
value (100); b) melting curve respectively.  
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Fig. 4. Multiple reference gene normalization: 18s, EF1, L17 and GAPDH of 
FLUX and VEN were analyzed with the software program Normfinder. 
-8
-6
-4
-2
0
2
4
18s EF1 GAPDH L17
Intergroup variation with intragroup 
variation as error
biological replicate. Relative gene expression was calculated with the ∆∆Ct method 
including the PCR efficiencies of the target and reference gene according to Pfaffl 
(Pfaffl, 2001).  
The mathematical model to determine the relative quantification of target genes 
as follows: sert, 5-ht3a and 5-ht3b, dopamine d2 and d3, mao and vmat mRNA 
expression in brain of D.labrax after FLUX and VEN exposures in comparison to the 
selected reference genes was performed according to Pfaffl (Pfaffl, 2001). Real-time 
RT-PCR allows quantification of rate transcripts and changes in gene expression 
(Pfaffl, 2001). Relative quantification is based on the expression levels of a target gene 
versus a reference gene. To calculate the expression of a target gene in relation to an 
adequate reference gene a mathematical model was established, although several 
mathematical models have been developed. This calculation is based on the 
comparison of the threshold values (Ct) at a constant level of fluorescence (Pfaffl, 
2004). After we obtained the values of Ct of target and reference samples was 
calculated the relative expression ratio I based on E and Ct of target samples versus a 
control, and expressed in comparison to a reference gene. This model is based with 
efficiency correction. The model used as follows:  
 
𝑟𝑎𝑡𝑖𝑜 (𝑅) =
(𝐸𝑡𝑎𝑟𝑔𝑒𝑡)∆𝐶𝑇(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑠𝑎𝑚𝑝𝑙𝑒)
(𝐸𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒)∆𝐶𝑇(𝑐𝑜𝑛𝑡𝑟𝑜𝑙−𝑠𝑎𝑚𝑝𝑙𝑒)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Equation 1. Formula used in the calculation of the relative quantification of a 
target genes in comparison to a reference gene 
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2.2.11. Statistical data analysis 
Treatment effects were evaluated by means of a two-way ANOVA, at a 5% 
significance level. Before our hypotheses being evaluated by two-way ANOVA, two 
tests may be approved to proceed with the evaluation: (i) normality test, (ii) equal 
variations. Some data had to be square root or rank statistical transformed in order to 
fit ANOVA assumptions. All tests were performed using the software Sigma plot 11.1 
version.  
2.2.12. Ethics statement 
 This study has been carried out in accordance with the national regulations on 
animal experimentation as detailed in the Portuguese Animals and Welfare Law 
(Decreto-Lei nº 197/96 – http://dre.tretas.org/dre/78012/) approved by the Portuguese 
Parliament in 1996. Animal experiments were approved by the Institutional ethics 
committee of CIIMAR. During the whole experiment, fish were humanely treated. 
Before being sacrificed, all fish were anesthetized using tricaine methanesulphonate 
(MS222, 100% W/W Powder for solution for fish treatment – Pharmaq MS-222®), and 
every effort was made to minimize suffering.  
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Table 2. Used primers for target genes (and accession numbers for corresponding sequences) 
 
Target gene 
(accession 
number) 
Primer sequence (5’→3’) Amplicon I 
Product 
(bp) 
Efficiency of 
the PCR 
reaction 
R2  of the 
PCR 
reaction 
Range Ct 
(cycle) of the 
PCR reaction 
Homology with other species 
Annealing 
temperature 
SERT (002060) 
F GTTGATGGCAGTGTTTGGTG 20bp 
109 92.0% 93.0 % 28-35 
Stegastes partitus – 96%;  
Takifugu rubripes– 93%;   Danio 
rerio – 88% 
56 ºC 
R GAAGATGGGGCAGATGTGTT 20bp 
5HT3B 
(00046560) 
F TCATCTGGCTGAATGTGTGC 20bp 
91 100 % 99.1 % 6-24 
Larimichthys 25rócea – 91%; 
Takifugu rubripes – 83%; Homo 
sapiens – 49% 
R AACTCCGCAGTCGTATTTCC 20bp 
5HT3A 
(00148200) 
F TGTATGTGGTGAACCTGCTG 20bp 
186 96.0 % 99.8 % 9-25 
Stegastes partitus – 75%;  
Poecilia Formosa – 65%; Danio 
rerio – 64% 
R TGTGTATCCCAGAATGAGGG 20bp 
Dopamine D2 
(00129960) 
F GGGTTGTTTTCAGGACCAAG 20bp 
121 107.0% 96.9 % 29-35 
Larimichthys crocea – 88%;  
Notothenia coriiceps – 79% R CGCAGAAAGGAGAAGAGCAA 20bp 
Dopamine D3 
(00076420) 
F GAATGAGCTGCGAGGTGAA 19bp 
80 92 % 96.6 % 28-34 
Larimichthys 25rócea – 96%;  
Poecilia Formosa – 91%; Danio 
rerio – 76% 
R CGTGGGTTGTTGGTATGAGA 20bp 
MAO 
(00054530) 
F GCCAATCACCTCAACCAAAC 20bp 
100 104.0 % 99.0 % 26-32 
Larimichthys 25rócea – 85%;  
Takifugu rubripes – 72%; Danio 
rerio – 62%; 
R AGGGACAAACCAAACACTGG 20bp 
VMAT 
(00018080) 
F CACCAAGAAGCTGCACAATG 20bp 
86 104.0 % 90.0 % 26-33 
Oryzias latipes – 90%;  Poecilia 
Formosa – 89%;  Danio rerio – 
81% R TGAAGGGGTTGGTTATCAGC 20bp 
* F-Foward; R-Reverse 
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2.3. RESULTS 
2.3.1. Identification of homology of the target sequences with others species  
Based on the degrees of homology with the same genes in mammals and other fish 
species, we were able to confirm the identity of the partial gene sequences for sert, 5-ht3a 
and 5-ht3b serotonin receptors, d2 and d3 dopamine receptors, mao and vmat in D. labrax. 
For the aim of sequence identification, we applied (i) blastx alignments, (ii) Clustal W 
alignments, and (iii) phylogenetic analyses.  
First, blastx alignments were performed, which showed high degrees of homology of 
the identified transcripts with other fish and mammal species, including human (Table 2). 
It is noteworthy that was recently identified by Tine et al., (2014) by phylogenetic tree, 
showing the relationships between D. labrax and other teleost fish species.  
Secondly, EMBL-EBI Clustal W2 alignments 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) were performed, which showed high degrees 
of homology of the identified transcripts with other fish species, and human. Multiple 
alignments of the deduced amino acid (a.a) sequences in D. labrax with other fish, as 
Oryzias latipes (O. latipes), Takifugu rubripes (T. rubripes), Homo sapiens (H. sapiens) 
and Danio rerio (D. rerio), are shown in the figures below. In the partial amino acid 
sequences of sert, 5-ht3a and b, d2 and d3, mao and vmat the highly conserved regions 
were marked in gray color. The amino acid sequences of sert, 5-ht3b, d3 and vmat had a 
higher homology among selected species showing a high degree of sequence similarity 
and hence, conservation. In contrast, the amino acid sequences of the 5-ht3a, d2 like 
receptor and mao (Fig. 5) were very dissimilar among the chosen species.   
Thirdly, results of the phylogenetic analyses revealed that sequences identified in D. 
labrax are evolutionarily closer to the same genes in other fish species, mainly D. rerio 
and T.rubripes than to mammals (Fig.6). Importantly, identified sequences of 
neurotransmitter genes and receptor subunits were characterized as similar to other 
species, since sequences always clustered together, with a certain distance to other 
subunits.  
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2.3.1.1. Multiple alignment 
a. sert multiple alignment  
O.latipes          MESKDTMMTSMQTKDKQEYE-EDKGSKQPEAQEEE–PHENANLPLVDGLADRGPKSVTS  
T.rubripes         METNNITMTRMLPLDTGDTEKEDFGGKTEEGGQEEGTEQEDSRLMVADGLAEKGPKTLTS 
H.sapiens          METTPLNSQKQLSACEDGEDCQENG-------------------VLQKVVPTPGDK---V  
D.labrax           ------------------------------------------------------------ 
D.rerio            ----------------------------------------------------------MP 2 
                                                                                
O.latipes          GSGQQVSNGFTTSTPQSPREALGTAVGAVGMPPASGGDTGASAPFGGLRTLVVQQTSLDR 117 
T.rubripes         DSGQQVSNGFTSS-PQTTREEVDKASGSTGTD---SGPVGAAGSAGGLRTLVVQQTSLER 116 
H.sapiens          ESGQ-ISNGYSAVPSPGAGDDTRHSIPATTTT------------------LVAELHQGE- 78 
D.labrax           -AGSLTHHG---SPNPAYSS-NNAVPVPVITQ--------------------------TD 29 
D.rerio            HQEQVIAHGNLCAPGPPNNAGYNSNPVPVIIQ--------------------------TE 36                       
 
O.latipes          PRETWSKKMDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYLLMAVFGGVPLFYMEL 177 
T.rubripes         PRETWSKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYLLMAVFGGVPLFYMEL 176 
H.sapiens          -RETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLPYTIMAIFGGIPLFYMEL 137 
D.labrax           SRDKWSKKMDFLLSVIGFAVDLGNVWRFPYICYQNGGGAFLIPYILMAIFGGVPLFYMEL 89 
D.rerio            SRDKWSKKMDFLLSVIGFAVDLGNVWRFPYICYQNGGGAFLIPYVLMAVFGGVPLFYMEL 96                     
 
O.latipes          ALGQFHRSGCISIWKHICPIFKGIGFAICIIALYIAFYYNTIMAWALYYLLSSFRPTLPW 237 
T.rubripes         ALGQFHHSGCISIWKHICPIFKGIGFAICIIALYIAFYYNTIMAWALYYLLSSFQSTLPW 236 
H.sapiens          ALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIMAWALYYLISSFTDQLPW 197 
D.labrax           ALGQFHRTGAISIWKHICPIFKGIGYAICIIALYVSFYYNTIIAWALFYFYSSFSSILPW 149 
D.rerio            ALGQFHRTGAISIWKHICPIFKGIGFAICIIALYVSFYYNTIIAWALFYFYSSFSSTLPW 156 
                     
O.latipes          TTCTNSWNTVNCYRYLSSDQNVTWSNLSTSPAEEFYTRQVLQVHLSSGLHQLGSVSWQLA 297 
T.rubripes         STCTNSWNTANCNQYMSTDHNVTWSNTSTSPAEEFYVRQVLQVHRSPGLHQLGSVSWQLA 296 
H.sapiens          TSCKNSWNTGNCTNYFSED-NITWTLHSTSPAEEFYTRHVLQIHRSKGLQDLGGISWQLA 256 
D.labrax           TNCDNVWNTPDCTNYFGID-NVTWTNSSKSPAEEFYTRNVLEIHKSSGLKNVGGVRWQLM 208 
D.rerio            TSCDNDWNTENCTNYFGKD-NVTWTNYSRSPAEEFYTRNVLAVHESSGLGNVGYIRWQLM 215 
 
O.latipes          LCLLFIFTIVYFSIWKGVKTSGKVVWVTATFPYLVLLILLIRGATLPGAWRGVVFYLKPD 357 
T.rubripes         LCLLFIFTIVFFSIWKGVKTSGKVVWVTATFPYLVLLVLLIRGATLPGAWRGVVFYLKPD 356 
H.sapiens          LCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGATLPGAWRGVLFYLKPN 316 
D.labrax           LCLFLIFTIVYFSLWKGVKTSGKVVWVTATLPYIVLFILLIRGATLPGAWRGVVFYLKPQ 268 
D.rerio            LCLFLIFTIVYFSLWKGVKTSGKVVWVTATLPYVVLLILMIRGATLPGAWKGVVFYLNPK 275 
                     
O.latipes          WQKLLSTTVWIDAAAQIFFSLGPGFGVLLAFASYNPFHNNCYKDALVTSSVNCLTSFLSG 417 
T.rubripes         WEKLLSTTVWIDAAAQIFFSLGPGFGVLLAFASYNPFHNNCYKDALITSSVNCLTSFLSG 416 
H.sapiens          WQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQDALVTSVVNCMTSFVSG 376 
D.labrax           WGKLLETSVWVDAAAQIFFSLGPGFGVLLALSSYNPFTNNCYRDAIVTSLVNCLTSFVSG 328 
D.rerio            WEKLKETSVWVDAAAQIFFSLGPGFGVLLALSSYNPFTNNCYRDAIVTSLVNCLTSFVSG 335 
                     
O.latipes          FVIFTVLGYMAEMRQQNVDVVAKDAGPSLLFIIYAEAIANMPAATFFAIIFFLMIIMLGL 477 
T.rubripes         FVIFTVLGYMAEMRQQDVDAVAKDAGPSLLFIIYAEAIANMPAATFFSIIFFLMIIMLGL 476 
H.sapiens          FVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPASTFFAIIFFLMLITLGL 436 
D.labrax           FVIFTVLGYMAEMRKVEVEDVAKDKGPSLLFITYPEAIANMMGSTFFAIIFFVMMITLGL 388 
D.rerio            FVIFTVLGYMAEQRNVNVEDVARDKGPSLLFITYPEAIANMVGSTFFAIIFFVMMITLGL 395 
                     
 
O.latipes          DSTFAGLEGVITAMLDEFPRLLAKRREWFVFGLVCVCYLGALSTLTYGGAFVVKLFEEYA 537 
T.rubripes         DSTFAGLEGVITAVLDEYPHVLVKRREKFVFGLVCVCYLGALSTLTYGGAFVVKLFEEYA 536 
H.sapiens          DSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVTLTFGGAYVVKLLEEYA 496 
D.labrax           DSTFGGLEAIITAVLDEYPDHFSHRRELFVLGLVVVCFLGSLSTLTNGGAYVVKLLEEFG 448 
D.rerio            DSTFGGLEAIITAVMDEYPDVLSHRRELFVLGLVVVCFLGSLSTLTKGGAYVVKLLEEFG 455 
                     
O.latipes          TGPAVITVVLLEVIAVSWFYGTSRFCNDIQVMLGFYPGCFWRVCWVAICPCFLLFIIISF 597 
T.rubripes         TGPAVITVVLLEVIAVSWFYGTKRFCNDIQVMLGFYPGIFWRVCWVAICPCFLLFIIISF 596 
H.sapies           TGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRICWVAISPLFLLFIICSF 556 
D.labrax           VGCSIIAVGFLEAIAVSWFYGINRFSNDVKSMLGKAPGLFWRVCWVAISPAFLAYIIVSS 508 
D.rerio            VGSSIIAIVFLEATAVSWFYGINRFSNDIKSMLGYTPGLFWKVCWVAISPAFLAYIIISS 515 
                   
O.latipes          LAFPPEVKLFNYTYPPWTTVLGYCIGVSSFICVPSYMVYYLLNAKGTFKQRLLKSITPE- 656 
T.rubripes         LAFPPEVRLFSYHYPLWTTALGYCIGVSSFICVPTYMIYCLIVTKGTFKQRLLKSITPV- 655 
H.sapiens          LMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIITPGTFKERIIKSITPE- 615 
D.labrax           ILKAPHLTLFDYTYPDWSITVGYIIGFSSFMWIPIYMVYKLVWTPGSLKQRLAVCLRPER 568 
D.rerio            LLNPQTLTLFDYEFPDWSITVGYIIGASSFIWIPIYMVYKLVWTPGSLKQRLAVCLRPER 575 
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O.latipes          PSSENHRDYIVTNAI- 671 
T.rubripes         PSTNQHRDIIVTSAL- 670 
H.sapiens          TPTEIPCGDIRLNAV- 630 
D.labrax           TIPDIHADSLNMATVP 584 
D.rerio            TLPDIHTDGMSLSPVP 591 
 
 
 
 
b. 5-ht3a receptor multiple alignment 
H.sapiens       ESSNYYAEMKFYVVIRRRPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLG 283 
T.rubripes      DNDDYYAEMKFHVVIRRRPLFYTVNLLLPSIFLMVMDIVGFYLPPDSGERVSFKITLLLG 288 
D.rerio         --------MYFWVLIRRRPLLYVVGLLIPSIFLMVVDVISFYLPPNSGTRITFKTSILLG 52 
D.labrax        EDG----------QLRRRATLYVVNLLIPSCFLITVDLFSFLLPPQTVDRSSFKMTLILG 207 
O.latipes       FGFN-QTVIVYTITMKRRSVLYIANFLLPVLFFLCLDFASFLMSDTGGEKVGFKVTVLLA 319 
 
H.sapiens       YSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWL 343 
T.rubripes      YSVFLIIVSDTLPATAIGTPLIGVYFVVCMALLVISLTETVLIVRLVHKQDLQTPVPDWV 348 
D.rerio         YTVIRVNLMDEIPATAIKTPLIGVFFAVCMALLLLSLAMSIFVVKLLHYSEKE------- 105 
D.labrax        YTVFLLIMNDLLPITGNTIPLINVFFSLCLALMVTSLLETIFITNLLSGSADFSPLPRWV 267 
O.latipes       VTVMQLILNDILPPSSDKIPLIAIYCIGIFTLMLLSLLETILVMYLIDKDQKLNENP--- 376 
                                
 
H.sapiens       RHLVLERIAWLLCLREQS------TSQRP-----PATSQATKTDDCSAMGNHCSHMGGPQ 392 
T.rubripes      KYVVLERAPVLFCIRRKHRLCSRLSSQGSDLDHYKDSSYGTSKDTQCTLHHTCEIGQRLS 408 
D.rerio         ----VKEMSMSACLLDKY------GS--------MDQSLESTFTSMKTLDEVDQSGGYEF 147 
D.labrax        RVFVLQFLGCLVCLPQKT-----------------KEPKGSGIKFSTAMAQRKADEGPPG 310 
O.latipes       -----------------------------------EDKHSPLPCCCTEIKKWIRCASAAK 401 
                                                                          
 
H.sapiens       DFEKSPRDRCSPPPPPREASLAVCG-LLQELSSIRQFLEKRDEIREVARDWLRVGSVLDK 451 
T.rubripes      EHERESGLLRLGLPPRRDPTPPVMNNILQEVMAIRHFLEKRDRCREVAKEWLQVGYVLDV 468 
D.rerio         DLSPEPDLFSLTEVSSSE---SPLEKILQEVMSLRLYLQEEDTEATSQSYWVQLCLKVDK 204 
D.labrax        EMMPVAEGKAVQELRSLG----------RDLQAIRLQVEQQLGGSKSSEEWIQVGFIIDR 360 
O.latipes       EDESFPKEGCSSPHTDVSLVMEKVYEELSEMKKSKYLLSSRTE-DEKPGYWTRVAEKINK 460 
 
 
 
 
H.sapiens       LLFHIYLLAVLAYSITLVMLWSIWQYA 478 
T.rubripes      LLFRVYLVAVVTYSITLGTLWSVWQVA 495 
D.rerio         LLFCIYLLLVFIYVMTLLLLWHSWSSA 231 
D.labrax        LLFGLYMVFISISFITIIIIWGNSYSQ 387 
O.latipes       VFAVFYIIAVLLFLSVLFTVWNIDGT- 486 
 
 
 
 
c. 5-ht3b receptor multiple alignment 
T.rubripes      ---------------MSLIWLFIFF–SAHASQCVPEKPKRSALNQLTRTLLRQYDCGVR 43 
D.labrax        ---------------MSLIWLTLLF–SAHLAECVPEKPKRSALNQLTRTLLRKYDCGVR 43 
O.latipes       ---------------MSLIWMMLLFSVSAHLADCLPVKPKRSSLNQLTRTLLRNYDSGVR 45 
D.rerio         MPRGTNAQVRVLGNVVRALGKLSLKCEVIPLAELVPEKPKRSALNQLTRLLLRKYNCGVR 60 
H.sapiens       ----------MLSSVMAPLWACILV–AAGILATDTHHPQDSALYHLSKQLLQKYHKEVR 48 
 
T.rubripes      PVHDWTSVTTVYIDLILLSVLDVDGKTQSITTSIWYRQVWTDEFLVWDPEEFDGLNEISL 103 
D.labrax        PVYNWTSLTTVYIDLILQSVLDVDGNTQSITTSIWYRQIWTDEFLVWDPEEFDGINEISL 103 
O.latipes       PVHNWTSTTTIYIDLILQSVLEVDGKTQSITTSIWCRQMWRDEFLVWDPEEFDGINEISL 105 
D.rerio         PVQNWTKPTTIYIDLIIQAVLDVDGQTQKVTTSIWYRQIWNDEFLVWDPDEFDGITEISL 120 
H.sapiens       PVYNWTKATTVYLDLFVHAILDVDAENQILKTSVWYQEVWNDEFLSWNSSMFDEIREISL 108 
 
T.rubripes      SSDAIWIPDVIVTEFVDGGKSPPIPYIYVNSSGSVKNYRPMQVVLACSLEMYAFPFDKQN 163 
D.labrax        SSDAIWVPDVIVSEFVDEGKSPTIPYVYVNSSGSVKNYRPMQVVVACSLEMYAFPFDKQN 163 
O.latipes       SSDALWVPDVIVSEFVKEGKSPPIPYVYVNSSGSVKNYRPIQAVLACSLEMYAFPFDKQN 165 
D.rerio         SSDAIWVPDLIISEFVDVGKSPVIPYVYVNCSGKVKNYKPIQVVSACHLEIYAFPFDKQN 180 
H.sapiens       PLSAIWAPDIIINEFVDIERYPDLPYVYVNSSGTIENYKPIQVVSACSLETYAFPFDVQN 168 
                 
T.rubripes      CSLTFRSWLHSVKEIDLALLRSAEDIANDKREFMNDGEWELQSIPSHYWHIHQDATDYAQ 223 
D.labrax        CSLTFRSWLHSVKEIDLALWRSAEAIANDKREFMNDGEWELLSIPSHYWIIHQDNTDYAH 223 
O.latipes       CSLTFRSWLHSVNEIDLALWRSADAIANDKREFMNDGEWELLSIPSQYRQISQDNTDYSQ 225 
D.rerio         CTLTFRSWLHSVSEVDLALWRPAEEIANDTREFMNDGEWELLGVPSRYWTLNLEDRDYAQ 240 
H.sapiens       CSLTFKSILHTVEDVDLAFLRSPEDIQHDKKAFLNDSEWELLSVSSTYSILQSSAGGFAQ 228 
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T.rubripes      IQFNVLIRRRPLLYVVGLLIPSIFLMLVDVTSFYLPLNSRTRIVFKVSILLGYTVFRVNI 283 
D.labrax        IQFNVLIRRRPLLYVVGLLIPSIFLMLVDVISFYLPLNSGTRIVFKISILLGYTVFRVNM 283 
O.latipes       IQFNLLIRRRPLLYVVGLLIPSIFLMLVDVVSFYLPLDSGTRIAFKISILLGYTVFRVNL 285 
D.rerio         IQFNVLIRRRPLLYVVGLLIPSIFLMVVDVISFYLPPNSGTRITFKTSILLGYTVIRVNL 300 
H.sapiens       IQFNVVMRRHPLVYVVSLLIPSIFLMLVDLGSFYLPPNCRARIVFKTSVLVGYTVFRVNM 288 
                 
  T.rubripes      TEELPSTAVRTPLIG--------------------------VFFAVCMALLMLSLIKSIL 317 
D.labrax        TDELPSTAVRTPLIG--------------------------VFFVVCMALLMLSLIKSIL 317 
O.latipes       TDDLPASAVKTPLIG--------------------------VFFVACKAMLMLSLTKSIL 319 
D.rerio         MDEIPATAIKTPLIGTVHPELFLISVHLLHSSKLSAVFATGVFFAICMALLLLSLAMSIF 360 
H.sapiens       SNQVPRSVGSTPLIG--------------------------HFFTICMAFLVLSLAKSIV 322 
 
T.rubripes      VVKLLHHNDKDVKQMSLSACLLDRYGSGGQEVTASALTSIRTLDSVDPSDEYELETSLEE 377 
D.labrax        VVKLLHHSEEEVKQMSVSACLLDKYGSTGQGFAESALTSIKTLDYINSSGDYELEPSLEE 377 
O.latipes       VVKLLHHSEKEVKQMSLSACLLDKYGSAGHSYTDSIFTSIKTLDHINQPEDFDVDYSLEE 379 
D.rerio         VVKLLHYSEKEVKEMSMSACLLDKYGSMDQS-LESTFTSMKTLDDVDQSGGYEFDLSPEP 419 
H.sapiens       LVKFLHDEQRGGQEQPF-LCLRGDTDADRPRVEPRAQRAVVTESSLYG------------ 369 
 
T.rubripes      DLVSLNEDQKVPSGLDWLLQELASLRLALHQEDTENSAQADWLELCLKLDRVLFWVYLLV 437 
D.labrax        DLLSLNEIQNPPSALEWVLQELASLRQALSEDDTESSTQAEWLALCSKLDCFLFRFYLLV 437 
O.latipes       DLLSLNEIQEVPSGLERLLQELVSLRLGFAQEDSESLAQSEWLSLCLRLDCLLFRFYLFV 439 
D.rerio         DLFSLTEVSSSESPLEKILQEVMSLRLYLQEEDTEATSQSYWVQLCLKVDKLLFCIYLLL 479 
H.sapiens       ------EHLAQPGTLKEVWSQLQSISNYLQTQDQTDQQEAEWLVLLSRFDRLLFQSYLFM 423 
 
T.rubripes      LVLYAGTLMLLWTSWSFA 455 
D.labrax        VVVYASTLLLLWASWSFA 455 
O.latipes       LALYTSTLLLLWASWSFA 457 
D.rerio         VFIYVMTLLLLWHSWSSA 497 
H.sapiens       LGIYTITLCSLWALWGGV 441 
 
 
                                 
d. Dopamine d2 multiple alignment 
O.latipes       MDVFTHYAYNDSFY-DNGTWSFNNTE-PLPKHTYNYYAMLLTLLIFVIVFGNVLVCMAVS 58 
T.rubripes      MDVFTQYAYNDSIF-DNGTWSANETT-KDETHPYNYYAMLLTLLIFVIVFGNVLVCMAVS 58 
D.rerio         MEVFTAYAFNESFF-ENASRDFNATE-QGGRHQYNYYAMLLTLLIFVIVFGNVLVCMAVS 58 
H.sapiens       MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATRLTLLIAVIVFGNVLVCMAVS 60 
D.labrax        MDVRTFWNQTTTHY-----------ETLLDTMFLIFNCTVLTLTLVFGLPGNLWVCWVVF 49 
 
O.latipes       REKALQTTTNYLIVSLAVADLLVATLVMPWVVY–LEVVGEWRFSKIHCDIFVTLDVMMC 116 
T.rubripes      REKALQTTTNYLIVSLAVADLLVATLVMPWVVY–LEVVGEWRFSKIHCDIFVTLDVMMC 116 
D.rerio         REKALQTTTNYLIVSLAVADLLVATLVMPWVVY–LEVVGEWRFSTIHCDIFVTLDVMMC 116 
H.sapiens       REKALQTTTNYLIVSLAVADLLVATLVMPWVVY–LEVVGEWKFSRIHCDIFVTLDVMMC 118 
D.labrax        RTKSLQTCNNALLVSLAASDLLKCSVDTPLLLFSFLRYGKDSQVSVPVCTLQQFTYALCS 109 
 
O.latipes       TASILNLCAISIDRYTAVAMPMLYNTRYSSRRRVTVMISVVWVMSFAISCPLLFGLNNTA 176 
T.rubripes      TASILNLCAISIDRYTAVAMPMLYNTRYSSRRRVTVMISVVWVLSFAISCPLLFGLNNTA 176 
D.rerio         TASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISVVWILSFAISCPLLFGLNNTV 176 
H.sapiens       TASILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNN–176 
D.labrax        CVQLLTLVSISVERFQAIAFPFQTERR---KARVRLWILSIWACGLILAVISLTLSEKAL 166 
 
O.latipes       TRDESLCVIANPAFVVYSSIVSFYVPFIITLLVYVQIYVVLRKRRKRVNTKPKQRICQAA 236 
T.rubripes      TRDQSLCFIANPAFVVYSSIVSFYVPFIVTLLVYVQIYVVLRKRRKRVNTKPKQRLCQAA 236 
D.rerio         THDDALCVIANPAFVVYSSIVSFYVPFIITLLVYVQIYVVLRKRRKRVNTK---RTCPVT 233 
H.sapiens       -ADQNECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTK---RSSRAF 232 
D.labrax        FYERLRYWDP---FGPYVLVPVWGLSLTVIVVHYVRIFKVVRQHRKKVFNR--------- 214 
 
O.latipes       DTDGATSLKDKCTHPEDVRLCTMIVKSNGSFPVNKKKVIFIKDVANDGEDLELDELNNSG 296 
T.rubripes      DPDIPTSLKDKCTHPEDVRLCTMIVKSNGSFPVNKKKVIFIKDGVNEVEGLELDELNYCG 296 
D.rerio         DMDMSSTIK-KCTHPDDVKLCTVIVKSSGNCPVNNKNVIFIKEVVNNGDDIQMDEITNRN 292 
H.sapiens       RAHLRAPLKGNCTHPEDMKLCTVIMKSNGSFPVNRRRV----EAARRAQELEMEMLSSTS 288 
D.labrax        ------GVQLRPTVSEHVWGWMSVPTS----------------APRTAPPHSFKTLPSVG 252 
 
O.latipes       SSQKQK–QLTQSVLGDTPATSHQQLMPSKANASPTSTPPTPPEEGQKAEKNED-TTDVL 353 
T.rubripes      GSHKQPPPQQQPRALGDTPATSHQLLMSTKANASPTSTPPTPPEEGQRTEKNGDPTKEAQ 356 
D.rerio         PSRQRK---------QDQSGGSQQNSRLVNSNLRETDISPPSPEAGVKPERNGNTSSITK 343 
H.sapiens       PPERTR--------YSPIPPSHHQLTLPDPSHHGLHSTPDSP----AKPEKNGHAKDHPK 336 
D.labrax        ---------------SGSPLPPRRTMLLVAEAGAPRAGSSTGGAPGRPPEIVGAVCLLTP 297 
                                   
O.latipes       TDPAPIVAKAFQTQALPNGKTQTSVKTMSKRKISQQKEKKATQMLAIVLGVFIICWLPFF 413 
T.rubripes      GNPAPVVA-------LRNGKTQTSLKDLSKRKISQQKEKKATQMLAIVLGVFIICWLPFF 409 
D.rerio         GAKAFEIQVS------PTGKTQTSVKTLNKRKISQQKEKKATQMLAIVLGVFIICWLPFF 397 
H.sapiens       IAKIFEIQT------MPNGKTRTSLKTMSRRKLSQQKEKKATQMLAIVLGVFIICWLPFF 390 
D.labrax        G---------------------------ARERGKKQMEGKVAQRFGYIIIAFTLFWVPMV 330 
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O.latipes       ITHILNTH–CTKCKVPAEMYNAFTWLGYVNSAVNPIIYTTFNVEFRKAFIKILHC---- 467 
T.rubripes      ITHILNTH–CTRCKVPAEMYNAFTWLGYVNSAVNPIIYTTFNVEFRKAFIKILHC---- 463 
D.rerio         ITHIVN-----TYCQVPPELYTAFTWLGYVNSAVNPIIYTTFNIEFRKAFIKILHC---- 448 
H.sapiens       ITHILNIH---CDCNIPPVLYSAFTWLGYVNSAVNPIIYTTFNIEFRKAFLKILHC---- 443 
D.labrax        VILLMNVISWQNTDKLLMELETSAMVLTCVQAAVDPLIYTLVTRQFRSELSKILSSIPGC 390 
         
 
       
e. Dopamine d3 multiple alignment 
T.rubripes      MAMFSSAEQPWNDSDGLSWAERNGSAEAPVQEE–RNYYAMLYSLLILAIVFGNVLVCLA 58 
D.labrax        MALFSSAERLWNESDSLGWDDRNESSEASGQDE–RNYYAMLYSLLILAIVFGNVLVCLA 58 
O.latipes       MAMFSSTEQLWNESEHLGWDERNDSSNKTGKDEGERNYYAMLYSLLILAIVFGNVLVCLA 60 
D.rerio         MAMFSSGEWLWNDSE-HSFTPGGNYSPASGVEEAKRNYYAMLYSLLILAIVFGNVLVCIA 59 
H.sapiens       MASLS------QLSSHLNYTCGAENSTGASQAR-PHAYYALSYCALILAIVFGNGLVCMA 53 
 
T.rubripes      VLRERSLQTTTNYLVVSLAVADLLVASLVMPWAVYLEVVGGAWLFSRLYCNIFVTLDVMM 118 
D.labrax        VLRERSLQTTTNYLVVSLAVADLLVASLVMPWAVYLEVVGGAWLFSRLYCNIFVTLDVMM 118 
O.latipes       VLRERSLQTTTNYLVVSLAVADLLVASLVMPWAVYLEVVGGAWLFNRLYCNIFVTLDVMM 120 
D.rerio         VLRERALQTTTNYLVVSLAVADLLVASLVMPWAVYLEVVGGAWLFSRLYCNVFVTLDVMM 119 
H.sapiens       VLKERALQTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMM 113 
 
T.rubripes      CTASILNLCAISIDRYTAVVMPVLYN–TTHRSRKRVFVMIAIVWVLAFAVSCPLLFGFN 176 
D.labrax        CTASILNLCAISIDRYTAVVMPVLYN–TTHRSRKRVFVMIATVWVLAFAVSCPLLFGFN 176 
O.latipes       CTASILNLCAISIDRYTAVVMPVLYN–TTHCSRKRVFAMIATVWVLAFAVSCPLLFGFN 178 
D.rerio         CTASILNLCAISIDRYTAVVMPVLYN–TTHSSRKRVSVMIATVWVLAFAVSCPLLFGFN 177 
H.sapiens       CTASILNLCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFN 173 
 
T.rubripes      TTDDPMVCSISNPDFVIYSSVVSFYLPFIITLLVYIRIYIFLR-MRRKRIAFGQPSGKVQ 235 
D.labrax        TTDDPMVCSISNPEFVIYSSVVSFYLPFIVTLLVYIRIYVFLR-MRRKRIAFGQASGKVQ 235 
O.latipes       TTDDPMVCSISNPDFVIYSSVVSFYLPFIVTLLVYIRIYVFLR-MRRKRIAFGQARGKVQ 237 
D.rerio         TTDDPAVCSISNPDFVIYSSVVSFYLPFAVTLLVYVRIYIFLR-RRRKKITFRQGSGKVQ 236 
H.sapiens       TTGDPTVCSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNS---Q 230 
                 
T.rubripes      PGSAPPSAETCLQ-ETPKAKQDLSPIRIKVQSVELPGPSKPSLLSGCLWRKRPKTGPVEN 294 
D.labrax        PGSTPPSVETCLQEETPKAKQDLSPIRIKVQSVEPSGPSKPNLLSGCLWRKRPKTGPVEN 295 
O.latipes       PGSTHPSVETCLQEETPKAKQDLSPIRIKVQSVESSGTSKPSLLSGCLWRKRPKTGPAQN 297 
D.rerio         PASAPPSVETCLQDDAHKEKRDLSPIRINVITESKEQVIRPRLLANCLRRKRPQTAPAEN 296 
H.sapiens       CNSVRP----------GFPQQTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREE 280 
 
T.rubripes      SMLPPVDTQNCCSISHASCGRTELDLEQERGEEGEEVAEGS-QREQPPVRMSCEVKDLSN 353 
D.labrax        SMLPPVDTHNCCSISHASCGRTEFELEQER---AEEEAEGNNQHEQPPVRMSCEVKDLSN 352 
O.latipes       SGLPPVDMQNYCSISHASCGRTEFDLEQGQ---VEQDASDSNQLELPPIRMNCEVKELSN 354 
D.rerio         SLLPPVITLNYCSISQASFARTEQDANREE--------EEGGDEEQVAVRG-CEVKKLAN 347 
H.sapiens       K------TRNSLSPTIAP-------------------------------KLSLEVRKLSN 303 
                 
  T.rubripes      GRTHTSLHPAYHSHTL----NTRFRTMHAREKKATQMLAIVLGVFLICWLPFFVTHILNT 409 
D.labrax        GRTHTSLRPVPHSHTN----NPRFRSMHAREKKATQMLAIVLGVFLICWLPFFVTHILNT 408 
O.latipes       GRTHTSLRPISHSQN-----NPRFRSMHAREKKATQMLAIVLGVFLICWLPFFVTHILNT 409 
D.rerio         GRTHTSLRPPRAAHAMVCPSQARCRSMHSKEKKATQMLAIVLGVFLICWLPFFVTHILNT 407 
H.sapiens       GRLSTSLKLG----------PLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNT 353 
 
T.rubripes      HCRTCYIPPGLYSAFTWLGYVNSALNPVIYTTFNIEFRRAFIKILSC 456 
D.labrax        HCRTCYVPPGLYSAFTWLGYVNSALNPIIYTTFNIEFRRAFIKVLSC 455 
O.latipes       HCRTCQIPPALYGAFTWLGYVNSALNPVIYTTFNIEFRRAFIKILSC 456 
D.rerio         HCRACHIPPEVYSAFTWLGYVNSALNPVIYTTFNIEFRRAFIKILSC 454 
H.sapiens       HCQTCHVSPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC 400 
 
 
 
 
       
f. vmat multiple alignment 
T.rubripes      MGKLDALWQLSLLRWLREERQSRKLILFIVFVALLLDNMLLTVVVPIIPSYLYSLDQS–58 
D.labrax        MGRLDALRQFNLLKWLREERQSRKLILFIVFVALLLDNMLLTVVVPIIPSYLYNLDES–58 
O.latipes       MGVLDALRQFRLIQWLREERQSRKLILFIVFVALLLDNMLLTVVVPIIPSYLYNLDES–58 
H.sapiens       ----MALSELALVRWLQESRRSRKLILFIVFLALLLDNMLLTVVVPIIPSYLYSIKHEKN 56 
D.rerio         MGLFDALRDFSLLTWLREERQSRRLILLIVFIALLLDNMLLTVVVPIIPSYLYTVDDE–58 
 
T.rubripes      KVLVLKNSTESQEASSGAFQTIVSLYDHTVKTVGSNATSRPTELVPARLPGTELPGN-AT 117 
D.labrax        TDVVLKNNTLSQHGPPGAFNSIVSLYDNTLRSSGSN---RSTDPVPSALAATELPQNSSS 115 
O.latipes       ADVALRNDSLSQKGPEGSFHTIVSLYDNSIRLSSSNFTTRPADPVPPTLVVTKLQQNSSD 118 
H.sapiens       ATEIQTARPVHTASISDSFQSIFSYYDNSTMVTGNATRDLTLHQTATQHMVTNASAVPSD 116 
D.rerio         AAQMVKNHSMTPLSPSSTFQSIVSLYDNTTRVTGFSPQMSTAGPMSLAPTFVSPQNQ-SD 117 
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T.rubripes      CPESTSMLTNENVKVGMMFASKATVQLITNPFIGPLTN---------------------- 155 
D.labrax        CPQSTKKLHNENVKVGMLFASKATVQLITNPFIGPLTNRIGYQLPIFAGFCIMFLSTIMF 175 
O.latipes       CPQSSSRLLNENVKVGMLFASKATVQLVTNPFIGPLTNRIGYQLPIFAGFCIMFLSTIMF 178 
H.sapiens       CPSEDKDLLNENVQVGLLFASKATVQLITNPFIGLLTNRIGYPIPIFAGFCIMFVSTIMF 176 
D.rerio         CPKADDQLLNENVKVGLLFASKATVQLITNPFIGPLTNRIGYQIPMFAGFCIMFVSTIMF 177 
 
T.rubripes      ------------------------------------------------------------ 
D.labrax        AFSSSYALLFLARSLQGVGSSCSSVAGMGMLASVYTDDEERGHAIGIALGGLALGVLVGP 235 
O.latipes       AFSSSYTLLFLARSLQGVGSSCSSVAGMGMLASVYTDDEERGHAIGIALGGLALGVLVGP 238 
H.sapiens       AFSSSYAFLLIARSLQGIGSSCSSVAGMGMLASVYTDDEERGNVMGIALGGLAMGVLVGP 236 
D.rerio         AFSSSYTLLFLARSLQGVGSSCSSVAGMGMLASVYTDDEERGNAIGIALGGLAMGVLVGP 237 
                                                                             
T.rubripes      ------------------------------------------------------------ 
D.labrax        PFGSVMYDFVGKTAPFLILAFLAVFDGALQLFVLQPTKVEPESQKGTPLLTLMKDPYILI 295 
O.latipes       PFGSVMYDFVGKTAPFLILAFLAVFDGALQLVVLQPTKVEPESQKGTPLLTLMKDPYILI 298 
H.sapiens       PFGSVLYEFVGKTAPFLVLAALVLLDGAIQLFVLQPSRVQPESQKGTPLTTLLKDPYILI 296 
D.rerio         PFGSVMYEFVGKTAPFLILAVLAVLDGALQLFVLQPSKVEPESQKGTSLITLMKDPYILI 297 
                                                                             
T.rubripes      ------------------------------------------------------------ 
D.labrax        AAGAICFGNMAIAMLEPTLPIWMMETMCARKWQLGVAFLPASISYLIGTNIFGTLAHKMG 355 
O.latipes       AAGAICFGNMAIAMMEPTLPIWMMETMCTRKWQLGIAFLPASISYLIGTNIFGTLAHKMG 358 
H.sapiens       AAGSICFANMGIAMLEPALPIWMMETMCSRKWQLGVAFLPASISYLIGTNIFGILAHKMG 356 
D.rerio         AAGSICFANMAIAMLEPALPIWMMETMCPRKWQLGIAFVPASISYLIGTNIFAVLAHKMG 357 
                                                                             
T.rubripes      ------------------------------------------------------------ 
D.labrax        RWLCALIGIMVVGISIICVPFATDIYGLILPNFGVGFAIGMVDSSMMPIMGYLVDLRHVS 415 
O.latipes       RWLCALIGMVLVGFSVICVPFAKDIYGLILPNFGVGFAIGMVDSSMMPIMGYLVDLRHIS 418 
H.sapiens       RWLCALLGMIIVGVSILCIPFAKNIYGLIAPNFGVGFAIGMVDSSMMPIMGYLVDLRHVS 416 
D.rerio         RWLCSLIGMLLVGISILCVPLAKDIYGLIVPNFGVGFAIGMVDSSMMPIMGYLVDLRHVS 417 
                                                                             
T.rubripes      ------------------------------------------------------------ 
D.labrax        VYGSVYAIADVAFCMGFALGPSIGGSIAESIGFPWLMTIIGIVDIFFAPLCLFLRNPPGQ 475 
O.latipes       VYGSVYAIADVAFCMGFALGPSIGGSIAENIGFPWLMTIIGIVDIFFAPLCIFLRNPPGQ 478 
H.sapiens       VYGSVYAIADVAFCMGYAIGPSAGGAIAKAIGFPWLMTIIGIIDILFAPLCFFLRSPPAK 476 
D.rerio         VYGSVYAIADVAFCMGFALGPSAGGAIARSIGFPWLMTIIGLVDIMFAPLCFFLRNPPAN 477 
                                                                             
T.rubripes      --------------------------------------- 
D.labrax        EEKIAILMDTNCSMKTRSYSTQGTYYQGENMDPEYDDYD 514 
O.latipes       EEKIAILMDSNCSMKTRSYSAQGTYYQGESMDPEYDDYD 517 
H.sapiens       EEKMAILMDHNCPIKTKMYTQNNIQSYPIGEDEESESD- 514 
D.rerio         EEKMAILMDSNCSMKTRSYSTQ-GSSYQMGDDFDPESPE 515 
 
 
 
g. mao multiple alignment 
O.latipes       MVERRMSPVWKWVLVLFALASVILNIGLIVVHSGRTPRCAAQXXXXXXLLAEHDARSGVF 60 
T.rubripes      MVEQRMNSVIKWALILFVLVSIILNIVLISMYSGRAPKCSAHR–AHPLRGKHDERSLVF 58 
H.sapiens       ------------------------------------------------------------ 
D.rerio         ------MTANAYDVIVIGGGISGLSAAKLLVDSGLNPVVLEARSRVGGRTYTVQNKETKW 54 
D.labrax        --------MYECRVILSSSKALGVLEGSLGMEVTSTG------------PQTIQKAEGES 40 
                                                                             
O.latipes       ADLSPEEYLQVQKYMLRQKDLD-ISTKQTTKPSENFLFLIDLLLPPKAEVLAFLDGNGPQ 119 
T.rubripes      ADLTWEEYSQVQQYMLKQKDLD-ISTNQITKPSENFLFLIDLSLPKKADALAYLDDGKGK 117 
H.sapiens       -----------GGKILKN-----VSVKRINASGN--------------RVLSVIADTE–28 
D.rerio         VDLGGAYIGPTQNRILRIAKQYGVKTYKVNEEES---------------LVHYVKGKS–97 
D.labrax        VTLGCSYTPSPSDSGELDIEWSVVSPDTTQKDQ---------------MLMSYTSGTK–83 
    
O.latipes       PERRATVVVFHGSTGFIKEYVVGPLPTPTYHRDVTREKYGMELPLTKRTVTVGEYVLMFQ 179 
T.rubripes      PTREATAVVFYGKSGYVKEYVVGPLPNPKYHRDVTKERYNTDIPINSRPVTIGEYAVLFE 177 
H.sapiens       ----------NGEKEFTGDIFFSSMP----VKDLVGGISGIEIPETVKSAAAN------- 67 
D.rerio         ----------YPFKGPFPPMWNPFAYMDYNNLWRTMDKMGMEIPKEAPWRAPH------- 140 
D.labrax        ---------------YVHSNHALAKGLSFAARDPSMGDASLSISLLSPAHSAT------- 121 
 
O.latipes       FFETEVFSKLQKVMAESFGVGPNRKLNAFEQMPRGVQSGDRKTWVSFFRDMSGMYIHPVG 239 
T.rubripes      FLEAEFFSKLQKLMKESFDVDDTNHLNAFEQMPRGVRSGDRSTWISFMRDMSGMYIHPVG 237 
H.sapiens       ------------------------------------------------------------ 
D.rerio         ------------------------------------------------------------ 
D.labrax        ------------------------------------------------------------ 
                                                                             
 
O.latipes       FEVLLNHQDLDPSRWSVERLLYNGVYFDSVEELNRAYDARSVERIVHKEAPDYGSLKPRP 299 
T.rubripes      LEVLVNHESVNSSQWTIQRVLYNGQYFDSVQALKEKYDRGSVKKILYTKSRDYGSLKPKT 297 
H.sapiens       ----LPYRDFVTVGLLVDRMLLK-----------NKTDIKTVNDIVPD------------ 100 
D.rerio         ----AEEWDKMTMQQLFDKICWTRS--------ARRFATLFVNVNVTSEP---------- 178 
D.labrax        ------------YQCKVKK--------------SPGVDMRKVSVVVMVKP---------- 145 
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O.latipes       GVPLQVGPQQFSEGGKRFSVRGNHVVYLDWSFAFGLSALTGMRVFDVRFRSERILYELSV 359 
T.rubripes      -KLLQVGPQLFHPEGKRYSISDNHVLYMDWSFAFGLSSLTGMRVFDVRFKDERILYELSV 356 
H.sapiens       ----------------------------CWIYVQDKNVKLGR------------------ 114 
D.rerio         -----------------------HEVSALWFLWYVKQCGGTMRIFSTTNGGQERKFAGGA 215 
D.labrax        ------------------------SVPKCWVEG--------------------------- 154 
                                                                           
 
O.latipes       QEAMSVYGSVTPGMIVTKFLDSSIGIGRFAHELVRGVDCPYDATYVDSVRYIDTPRAVRF 419 
T.rubripes      QEAMSVYGSVTPGMGLTKFFDTSIGIGRFAHQLVRGVDCPYEAAYITTYRYIDAPNPIKF 416 
H.sapiens       ---IQIFNNWSPYMVKEPENTVSLGLEYFCDEGDDFWNMPEEECIALAS---DELVRIGV 168 
D.rerio         NQISEGMQKELGDRVKLSKAVCSIDQTGDLVEVRTVNEEVYKAKYVILAIPPGLNLKIHF 275 
D.labrax        ---GELVGEAVSLHCQSAKGSTPLKYTWRRESARPMPAPATQSKHSVTG-------ELKI 204 
 
O.latipes       RNSICVFEHNMGQPLRRHFADFFHHSYGGMANSALVFRTITAIGNYDYMWDFIFYQSGSV 479 
T.rubripes      EDSICIFEHNLGQPLRRHFSDFFHNSYGGMVNSALVMRTITAIGNYDYMWDFIFYQSGSV 476 
H.sapiens       IDCGAVLSAHR-ERVKKAYPAYFDS-----------YKDLPEIIDFLNTLDNLYCVG--- 213 
D.rerio         NPELPPLRNQLIHRVPMGSVIKCMVYYKENFWRKKGYCGSMVIEEEDAPIGLTLDDTKPD 335 
D.labrax        TNHSQSFAGIYLCEVNN------------------------AVGAEHCRINLKVNKP--- 237 
                       
O.latipes       EAKVHATGYISSSYMVHGSRRHGHQVAEKVLGNIHTHFINFKVDLDVGGVKNMFQTKDME 539 
T.rubripes      EAKVHATGYISSSYMMEGSLNYGHQVAEKVLGNLHTHFINFKVDLDVAGVKNVFQTKDMK 536 
H.sapiens       --------------------RNGQHRYNNMDHSMMTSLL--------------------- 232 
D.rerio         GSVPAIMGFILARKSRKLANLTRDERKRRICEIYARVLGSEEALYPVHYEEKNWCEEEYS 395 
D.labrax        -----------------------PNRAAVIVGTIVGSLL--------------------- 253 
                                         
O.latipes       FVNVSLPWMPDRSAMVPQLVEKQLKTEKEAALRYDTKTPRYLHIASNATNSWGHQRSYRL 599 
T.rubripes      FVNTSVPWQPGHHAMIPQLVEKQLNTEQEAALRYNTKTPRYLHVASPKVNRWGHPRSYRL 596 
H.sapiens       ------------------AVDNILSGKNDKSAIWNVNTEEEYHEKGDRNE---------- 264 
D.rerio         GGCYTAYFPPGIMTQFGRVLREPVGRLYFAGTETATEWSGYMEGAVQAGERASREVMCAM 455 
D.labrax        ------------LIFILLVFLGLLYWKLSNRHHYEKEFSNDIREDAPPPESR-------- 293 
 
O.latipes       QVFSFAGDHLPESQAEERSMSWARYKVAITKHKDQEQTSSSLYSQNDMWTPAVDFSKYIE 659 
T.rubripes      QVFTFAGDHLPESEPEERSMSWARYKVAITKQKDLEQTSSSLYNQNNIWSPTVDFSKYID 656 
H.sapiens       ------------------------------------------------------------ 
D.rerio         GKLHAS–QIWQSEPESMDVPARPFVTTFWERN---------------LPSVGGFLKFMG 498 
D.labrax        ------------------------------------------------------------ 
                                                                           
O.latipes       DDENIDNEDLVAWVTTGFLHIPHAE----------------------------------- 684 
T.rubripes      DNESIVDQDLVAWVTAGFLHIPHAEDIPNTVTVGNGGGVLLRPHNYFDEDPSIHSADGVY 716 
H.sapiens       ------------------------------------------------------------ 
D.rerio         VSSFLAAATAAGLVACKKGLLPRC------------------------------------ 522 
D.labrax        ------------------------------------------------------------ 
                                                                             
O.latipes       -------------------------------------------- 
T.rubripes      INPSSTDSCENNRVACLAQETCSPVLEPFTYHGFDGVMKFQDWQ 760 
H.sapiens       -------------------------------------------- 
D.rerio         -------------------------------------------- 
D.labrax        -------------------------------------------- 
 
 
 
Fig. 5. Multiple alignments of the deduced amino acid sequences for sert, 5ht3a and 5-ht3b, dopamine 
dopamine d2 and d3, mao and vmat in D. labrax with other fish species and human using EMBL-EBI 
Clustal W2 alignments software.  
SERT: D.labrax  002060; H.sapiens:  EAW51223.1; D.rerio: NP_001170930.1; T.rubripes: XP_003968295.2; 
O.latipes:. XP_004075963.2. 5-HT3A: D.labrax  00148200; H.sapiens AAM21131.1; D.rerio XP_009296619.1; 
T.rubripes XP_011609568.1; O.latipes XP_011490786.1. 5-HT3B: D.labrax 00046560; H.sapiens 
NP_006019.1; D.rerio XP_009293724.1; T.rubripes XP_009293724; O.latipes XP_004076882.1. D2: D.labrax 
00129960; H.sapiens AAB26819.1; D.rerio NP_898891.1; T.rubripes XP_003968417.1; O.latipes 
XP_004075461.1. D3: D.labrax 00076420; H.sapiens  AAB08750.1; D.rerio  AAH76352.1; T.rubripes 
XP_004081111.1; O.latipes XP_004081111.1. VMAT: D.labrax 00018080; H.sapiens NP_003045.2; D.rerio 
NP_001243154.1; T.rubripes XP_011618602.1; O.latipes XP_004077262.1. MAO: D.abrax 00054530; 
H.sapiens EKC75134.1; D.rerio AAO16681.3; T.rubripes XP_003964455.2 ; O.latipes XP_011477037.1.  
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2.3.1.2. Phylogenetic trees based on the multiple alignments 
 
 
 
a) 
b) 
c) 
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Fig. 6. Phylogenetic tree based on the multiple alignments (Clustal W) of related proteins from sert, 
5ht3a and b, dopamine d2 and d3, mao and vmat of D. labrax and others species. Evolutionary 
history was inferred using neighbor-joining (Mega 6 software) method and the percentage of 
concordance based on 1000 bootstrap iterations is shown at the nodes.  
a)SERT: D.labrax  002060; H.sapiens:  EAW51223.1; D.rerio: NP_001170930.1; T.rubripes: 
XP_003968295.2; O.latipes:. XP_004075963.2; Ciona intestinalis: XP_002125543.1. b) 5-HT3A: D.labrax 
00148200; H.sapiens AAM21131.1; D.rerio XP_009296619.1; T.rubripes XP_011609568.1; O.latipes 
XP_011490786.1; Ciona intestinalis: XP_009862074.1 and b) 5-HT3B: D.labrax 00046560; H.sapiens 
NP_006019.1; D.rerio XP_009293724.1; T.rubripes XP_009293724; O.latipes XP_004076882.1; Ciona 
intestinalis: XP_009862074. c) D2: D.labrax 00129960; H.sapiens AAB26819.1; D.rerio NP_898891.1; 
T.rubripes XP_003968417.1; O.latipes XP_004075461.1; Ciona intestinalis: XP_009860861.1 and c) D3: 
D.labrax 00076420; H.sapiens  AAB08750.1; D.rerio  AAH76352.1; T.rubripes XP_004081111.1; O.latipes 
XP_004081111.1. d) VMAT: D.labrax 00018080; H.sapiens NP_003045.2; D.rerio NP_001243154.1; 
T.rubripes XP_011618602.1; O.latipes XP_004077262.1; Ciona intestinalis: XP_009860861.1 e) MAO: 
D.abrax 00054530; H.sapiens EKC75134.1; D.rerio AAO16681.3; T.rubripes XP_003964455.2 ; O.latipes 
XP_011477037.1; Ciona intestinalis: XP_002123175.1  
d) 
e) 
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2.3.2. Quantification of SERT, 5-HT3A and 5-HT3B, dopamine D2 and D3, MAO 
and VMAT mRNA expression in brain of D. labrax after FLUX and VEN 
exposures  
The effects of FLUX and VEN exposure in the mRNA expression of brain receptors 
transcripts was evaluated by qPCR-RT. Relative quantification was used for comparison 
of different mRNA expression of neurotransmitter genes and receptor subunits in the brain 
of D.labrax. Results are presented separately for VEN and FLUX exposure, first 
transporters of monoamines; second receptors of serotonin and dopamine; third and final 
the degrading enzyme.  
 
2.3.2.1. Transporters of monoamines 
2.3.2.1.1. Specific transporter of serotonin: sert 
Transporter of monoamines, specific transporter, mRNA expression levels after 
VEN and FLUX exposure to different concentration are displayed in Fig.7 (A) and Fig.8 
(B). No significant differences were observed for the mRNA expression of SERT in 
response to VEN exposure. In contrast, SERT mRNA was significantly increased in 
response to FLUX exposure at day 1 in the 50 µg/L treatment group compared to the 
solvent control.  
A. RESPONSE TO VEN 
Fig. 7. Gene expression of the specific transporter of serotonin - sert - after exposure to two 
different concentrations (0.01 µg/L; 1 µg/L) of venlafaxine (A) for 21 days and 7 days of recovery 
period. Differences in genes expression were analyzed between treatments and the solvent 
control (CTR S). Different letters denote significant differences at p<0.05. 
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2.3.2.2. Non-specific transporter: vmat 
 
Non-specific transporter of monoamines, vmat, mRNA expression levels after VEN 
and FLUX exposure to different concentration are displayed in Fig.9 (A) and Fig.10 (B). A 
significant recovery was observed for the mRNA expression of vmat in response to VEN 
exposure at day 28 in 1 µg/L treatment group compared to the control. In contrast, vmat 
mRNA was significantly increased in response to FLUX exposure at day 1 in the 50 µg/L 
treatment group compared to the solvent control.  
 
 
 
 
 
 
 
 
 
 
 
B. RESPONSE TO FLUX 
Fig. 8. Gene expression of the specific transporter of serotonin - sert - after exposure to two 
different concentrations (0.5 µg/L; 50 µg/L) of FLUX (B) for 21 days and 7 days of recovery 
period. Differences in genes expression were analyzed between treatments and the solvent 
control (CTR S). Different letters denote significant differences at p<0.05.  
a 
b 
a,b a,b 
a 
b 
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Fig. 10. Gene expression of the non-specific transporter of monoamines - vmat -  after exposure 
to two different concentrations (0.5 µg/L; 50 µg/L) of FLUX (B) for 21 days and 7 days of recovery 
period. Differences in genes expression were analyzed between treatments and the solvent 
control (CTR S). Different letters denote significant differences at p<0.05. 
A. RESPONSE TO VEN 
B. RESPONSE TO FLUX 
Fig. 9. Gene expression of the non-specific transporter of monoamines - vmat - after exposure to 
two different concentrations (0.01 µg/L; 1 µg/L) of VEN (A) for 21 days and 7 days of recovery 
period. Differences in genes expression were analyzed between treatments and the solvent 
control (CTR S). Different letters denote significant differences at p<0.05. 
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2.3.2.3. Receptors of serotonin 
2.3.2.3.1. 5-ht3a receptor 
Ion channel receptor of serotonin subtype 5-ht3a mRNA expression levels after VEN 
and FLUX exposure to different concentration are displayed in Fig.11 (A) and Fig.12 (B). 
Significant differences was observed for the mRNA expression of 5-ht3a in response to 
VEN exposure at day 21 in 1 µg/L treatment group compared to the solvent control. 
Although, 5-ht3a mRNA was significantly increased in response to FLUX exposure at day 1 
in the 50 µg/L treatment group compared to the solvent control. In response to VEN 
observed chronic induction and in response to FLUX there was an acute induction in 
highest concentration.  
A. RESPONSE TO VEN 
  
 
 
 
 
 
Fig. 11. Gene expression of receptor of serotonin subtype 5-ht3a after exposure to two different 
concentrations (0.01 µg/L; 1 µg/L) of VEN (A) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05.
b 
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2.3.2.4. 5-ht3b receptor 
 
Ion channel receptor of serotonin subtype 5-ht3b mRNA expression levels after VEN 
and FLUX exposure to different concentration are displayed in Fig.13 (A) and Fig.14 (B). 
No significant differences were observed for the mRNA expression of 5-HT3B in response 
to VEN exposure in all exposure days. We observed in VEN exposure a tendency chronic 
at day 21, but without significant differences (p<0.147). In contrast, 5-ht3b mRNA was 
significantly increased in response to FLUX exposure at day 1 in the 50 µg/L treatment 
group compared to the solvent control.  
 
 
 
 
 
 
 
 
 
 
 
B. RESPONSE TO FLUX 
Fig. 12. Gene expression of receptor of serotonin subtype 5-ht3a after exposure to two different 
concentrations (0.5 µg/L; 50 µg/L) of FLUX (B) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05. 
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         A. RESPONSE TO VEN 
  
 
B. RESPONSE TO FLUX 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 14. Gene expression of receptor of serotonin subtype 5-ht3b after exposure to two different 
concentrations (0.5 µg/L; 50 µg/L) of FLUX (B) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control 
(CTR S). Different letters denote significant differences at p<0.05. 
Fig. 13. Gene expression of receptor of serotonin subtype 5-ht3b after exposure to two different 
concentrations (0.01 µg/L; 1 µg/L) of VEN (A) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05.
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2.3.2.5. Receptors of dopamine 
2.3.2.5.1. Dopamine d2 receptor 
 
Receptor of dopamine subtype d2 mRNA expression levels after VEN and FLUX 
exposure to different concentration are displayed in Fig.15 (A) and Fig.16 (B). A significant 
recovery was observed for the mRNA expression of dopamine d2 in response to VEN 
exposure at day 28 in 1 µg/L treatment group compared to the solvent control. In contrast, 
dopamine d2 mRNA was significantly increased in response to FLUX exposure at day 1 in 
the 50 µg/L treatment group compared to the solvent control.  
A.RESPONSE TO VEN 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 15. Gene expression of receptor of dopamine subtype d2 after exposure to two different 
concentrations (0.01 µg/L; 1 µg/L) of VEN (A) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05.
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B.RESPONSE TO FLUX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Fig. 16. Gene expression of receptor of dopamine subtype d2 after exposure to two different 
concentrations (0.5 µg/L; 50 µg/L) of FLUX (B) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05.
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2.3.2.5.2. Dopamine d3 receptor 
 
Receptor of dopamine subtype d3 mRNA expression levels after VEN and FLUX 
exposure to different concentration are displayed in Fig.17 (A) and Fig.18 (B). A significant 
recovery was observed for the mRNA expression of dopamine D3 in response to VEN 
exposure at highest concentration, 1 µg/L treatment group compared to the solvent 
control. In contrast, dopamine d3 mRNA was significantly increased in response to FLUX 
exposure at day 1 in the 50 µg/L treatment group compared to the solvent control. Also, 
recovery was observed for the mRNA expression of dopamine d3 in response to FLUX 
exposure at lower concentration, 0.5 µg/L.  
 
 
A.RESPONSE TO VEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17. Gene expression of receptor of dopamine subtype d3 after exposure to two different 
concentrations (0.01 µg/L; 1 µg/L) of VEN (A) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05.
b 
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        B.RESPONSE TO FLUX  
 
 
 
 
 
 
 
2.3.2.6. Degrading enzyme: mao 
 
Degrading enzyme mRNA expression levels after VEN and FLUX exposure to 
different concentration are displayed in Fig.19 (A) and Fig.20 (B). A significant recovery 
was observed for the mRNA expression of mao in response to VEN exposure at highest 
concentration, 50 µg/L, compared to the control group. In contrast, mao mRNA was 
significantly increased in response to FLUX exposure at day 1 and day 21 in the 50 µg/L 
treatment group compared to the solvent control. There were chronic and acute inductions 
to response FLUX. 
The gene expression data of the target brain receptors show that there is an 
individual pattern of mRNA expression under pressure from the different two 
contaminants. Both responses are different each target gene. 
 
 
 
 
 
 
 
 
Fig. 18. Gene expression of receptor of dopamine subtype d3 after exposure to two different 
concentrations (0.5 µg/L; 50 µg/L) of FLUX (B) for 21 days and 7 days of recovery period. 
Differences in genes expression were analyzed between treatments and the solvent control (CTR 
S). Different letters denote significant differences at p<0.05.
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A.RESPONSE TO VEN 
       B.RESPONSE TO FLUX 
 
 
 
 
 
 
 
 
 
Fig. 19. Gene expression enzyme mao after exposure to two different concentrations (0.01 µg/L; 
1 µg/L) of VEN (A) for 21 days and 7 days of recovery period. Differences in genes expression 
were analyzed between treatments and the solvent control (CTR S). Different letters denote 
significant differences at p<0.05.
Fig. 20. Gene expression of enzyme mao after exposure to two different concentrations (0.5 µg/L; 
50 µg/L) of FLUX (B) for 21 days and 7 days of recovery period. Differences in genes expression 
were analyzed between treatments and the solvent control (CTR S). Different letters denote 
significant differences at p<0.05.
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2.4. DISCUSSION 
 
The increasingly use of antidepressants by humans has resulted in their presence in 
the WWTP and ultimately in the aquatic ecosystems, posing  an ever urgent problem for 
aquatic ecosystems worldwide (Schultz and Furlong, 2008; Vasskog et al., 2008; Kolpin et 
al., 2002; Metcalfe et al., 2003b; Gomez et al., 2006; Metcalfe et al., 2003a).  Despite of 
the knowledge of environmental presence at low concentrations, the chronic effects of 
antidepressants on aquatics organisms are not well described or understood. Until now, 
no comparative studies on the ecotoxicity of SSRIs and SNRIs were performed in ﬁsh 
species, establishing whether they share a common mechanisms of toxicity since both 
share a common pharmacological activity (Brooks et al., 2003; Kreke and Dietrich, 2008; 
Owens et al., 1997). Overall, there is not enough studies to determine which PP are of 
concern (Brooks et al., 2003). Many studies focused on the freshwater fish species in 
behavioral alteration of PP on aquatic species, (Bisesi et al., 2014; Gaworecki and Klaine, 
2008; Menningen, 2011; Thomas et al., 2012), locomotor activity or  behavior, such as the 
ability to capture prey (Bisesi et al., 2014; Dufour-Rainfray et al., 2010; Gaworecki and 
Klaine, 2008; Larson and Summers, 2001; Lucki, 1998; Weinberger and Klaper, 2014), 
reproduction (Best et al., 2014; Foran et al., 2004; León-Olea et al., 2014; Prasad et al., 
2015; Santos et al., 2010; Weinberger and Klaper, 2014) as well as appetite or feeding 
(Menningen, 2011).   
It is very important to consider the potential effects of SSRIs and SNRIs on aquatic 
vertebrates at environmental concentrations and under chronic conditions, since the 
pharmacological targets are well conserved among species and pharmaceuticals are 
continuously release into the ecosystem. Brooks and colleagues (2003) suggested that 
chronic studies with environmental concentrations of pharmaceuticals are crucial and 
useful to assess aquatic ecosystem responses (Brooks et al., 2003). Neuroamine 
receptors may become desensitized by chronic exposure and allow further release of 
monoamines, allowing the therapeutic function of the chemical (Bisesi et al., 2014).  
It is necessary to increase the knowledge about the responsse to chronic exposure 
in aquatic organisms and to compare two distinct PPs (SSRI and SNRI) on the 
neurotransmitter system to understand whether mRNA expression of the 
neurotransmitters system is altered when aquatic organisms are exposed to SSRIs and 
SNRIs and whether the pharmaceuticals classes of antidepressants have similar or 
different mechanisms of toxicity. Hence, the focus of this thesis was to understand how 
aquatic exposure to the antidepressant FLUX and VEN affect neurotransmission gene 
mRNA expression in the brain of juvenile European seabass and compare the chronic 
effects of SSRI and SNRI. Altered neurotransmitter gene expression may result from 
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antidepressants-induced epigenetic modifications, which could subsequently impact 
protein expression, synaptic plasticity and addictive behavior.  
Also, we chose a marine fish species D. labrax, since few studies were performed 
elucidating the chronic response or mRNA expression after antidepressants exposure in 
marine species.  
 
2.4.1. Homology of the target sequences with others species 
The concern regarding an ecotoxicological impact of antidepressants in fish is based 
on the assumption that both the serotonergic system and dopaminergic neurotransmitter 
system is conserved between different vertebrate species including humans. Since both 
selected PP in this study, a SSRI (FLUX) and a SNRI (VEN), target the serotonin and 
dopamine neurotransmitter system, adverse effects can be expected. Our first analyses 
aimed to confirm the sequence identities of the available sequences of the 
neurotransmitter genes for European seabass, in particular of the available 
neurotransmitter receptor subunits, by comparing them to sequences of other vertebrate 
species including teleost fish.  
 Bioinformatic analyses performed on seabass sequences demonstrated that in 
general the amino acid sequences of the neurotransmitter genes and receptors of D. 
labrax are highly similar to other vertebrate species as O.latipes, T. rubripes, H. sapiens, 
and D. rerio. These results indicate a high degree of conservation in vertebrates between 
serotonin and dopamine receptors, their transporter and degrading enzyme.  
Topology analysis revealed that partial amino acid sequences for the serotonin and 
dopamine receptors, transporters and degrading enzyme identified in this study are 
analogous. Moreover, the high degree of homologies with other fish and mammals seen 
after multiple alignments (Fig.5), and clustering of the sequences with other fish species in 
phylogenetic analysis (Fig.6) consequently demonstrate the presence of the genes in the 
brain of D. labrax and their sequence identity, which can be used to deduce a hypothetical 
function to the genes due to their sequence homology.  
Concerning the dopamine receptors, only the subtype d3 was similar with others 
selected species, while d2 receptor was more dissimilar.  
Sequence homology allows the assumption that D. labrax genes have similar 
functions as in other vertebrates. The potential functions of the genes targets are different. 
The receptors of serotonin 5-ht3a and 5-ht3b, ligand-gated ion channel, are responsible for 
fast transmitting signals between neurons or release the monoamines (Chameau and Van 
Hooft, 2006). The receptors of dopamine, dopamine d2 and d3, promote signal 
transmission between neurons to different functions, as modulatory action to sensory 
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perception in the retina and olfactory bulb, regulation of prolactine release in the pituitary 
gland, control of body temperature, food intake and sexual behavior in the hypothalamus 
(Callier et al., 2003). The storage process of neurotransmitters is performed by vmat that 
is release at the synapse following neuronal membrane depolarization. When 
monoamines are not stored in presynaptic vesicles by vmat, they are degraded by mao 
enzyme (Maximino, 2012). Sert gene serves the important function of taking up serotonin 
release during serotonergic neurotransmission (Descarries and Riad, 2012). Thus, the 
main output of homology of the target sequences with others vertebrates is that the 
obtained sequences cluster and align well improving the available knowledge of 
similar/difference between species.  
 
2.4.2. Neurotransmitters mRNA expression with FLUX and VEN exposure  
 Antidepressants are known to act on receptors of the neural system and at the level 
of neurotransmission. This indicates probable changes in target neural system and their 
mRNA expression, as we observed in this study. We were initially interested in FLUX and 
VEN because of four main reasons: they are highly prescribed drugs, they have a  
potential to interfere with behavior (Brooks et al., 2003) and possess physical-chemical 
properties that favor bioaccumulation (Weinberger and Klaper, 2014). These classes of 
antidepressants are relatively lipophilic and are prone to cross the blood-brain barrier and 
to interact with therapeutic targets (Bisesi et al., 2014; Brooks, 2014).   
There was acute up regulation in all target genes, on 1st day of exposure of FLUX, 
except for mao that had chronic effects showing a pattern of increased expression at day 
21. Two recent studies showed the FLUX can regulate the  transcription of genes involved 
in biological pathways (Park et al., 2012; Thomas et al., 2012). FLUX and another SSRI, 
sertraline, can influence the transcription of many genes in zebrafish (Park et al., 2012). 
The larval zebrafish, 76 hours post fertilization (hpf), were exposed for 96h, to two SSRIs 
at two concentrations: 25 and 250 µg/L. They observed by microarray that the same five 
genes were differentially regulated in both SSRIs indicating shared molecular pathways, 
which were recognized to be involved in regulation of the stress response, as myogenin 
and FKBP5. Consistent with microarray results, FKBP5 gene expression was shown to be 
downregulated after exposure to the SSRIs and the pattern of gene expression changes 
was similar to that observed by microarray analysis. Most of the genes affected by FLUX 
were involved in transcription regulation and signal transduction, as SLC5A11 (solute 
carrier family 5 (sodium/inositol cotransporter) and SLC6A11 (solute carrier family 6 
(neurotransmitter transporter), response to stress, as myogenin and FKBP5, among 
others. As in our study there were no changes in VEN exposure at 21 day of SERT 
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(SLC6A4) mRNA, in contrast with the exposure to FLUX in which there was a significantly 
acute induction at the first day in the highest concentration (50 µg/L). Consequently, in the 
same study they showed that no changes in expression of genes involved with 
reproductive functions were observed at low concentrations of both SSRIs, (Park et al., 
2012). We know that sert is the target of SSRIs and SNRIs. Benmansour et al. (2002) 
show that SSRI-induced downregulation of the transporter. Interestingly, in 2000 was 
shown that low expression of sert in brain of mammal’s results in abnormal serotonin 
transmission in the major component in brain (hippocampus) and was correlated with 
cognitive impairment, like Alzheimer’s disease (Hu et al., 2000). Previous research 
showed that vertebrates, like aquatic species, when exposed to PP exhibit differences in 
behavior. Aggression frequently coincides with these emotionally differences in fish. Also, 
in rats, it was demonstrated that increased aggression are accompanied by an alteration 
in the expression of key genes that regulate system of serotonin neurotransmission 
included SERT in select brainstem nuclei (Kerman et al., 2011).   
In our study, we demonstrated that serotonin receptors 5-ht3a was down regulated 
after VEN exposure at day 21. Although, 5-ht3b mRNA had a tendency to inhibition at day 
21, no significant differences were observed. A limited number of studies focused on the 
association of gene variants encoding the subtypes of serotonin receptor with the different 
responses of gene transcription due to exposure to antidepressants (O’Leary et al., 2014). 
Interestingly, the knockout of a subtype of these receptors, 5-ht3a, in mice resulted in 
resistance to FLUX exposure inducing anxiety (Smit-Rigter et al., 2012), suggesting a role 
for the 5-ht3a in the reported negative effects of SSRI treatment. Another study showed 
that FLUX can inhibit binding of a 5-ht3 receptor antagonist in neuroblastoma-glioma 
hybrid cells (Lucchelli et al., 1995). The receptor 5-ht3 is distributed throughout the brain 
and CNS, with relatively high concentrations in the spinal cord and brainstem (area 
postrema), where it regulates vomiting. The chronic treatment to FLUX leads to the 
desensitization of the 5-ht3 receptor (Fan, 1994).  It is noteworthy that, the SSRIs and 
SNRIs exerts its therapeutic effect by inhibiting monoamine transports, thus reducing the 
reuptake of the serotonin and activity of serotonin transporter protein (sert) at presynaptic 
neuronal membranes (Charoenphandhu et al., 2013; Descarries and Riad, 2012), which 
ultimately lead to an increase of serotonin concentration in the synaptic clefts. Down 
regulation in the expression of these genes, 5-ht3a and 5-ht3b, would reduce the sensitivity 
serotonin, and role in neurotransmission. Stimulation of 5-HT3 receptor leads to ion influx 
via an ion channel, such as Na+, K+ efflux and Ca+ influx, inducing a depolarization 
mediated by cation flow (Reiser, 1991). The major consequence of depolarization is a 
rapid increase in cytosolic Ca2+ concentration from the extracellular membrane followed 
by neurotransmitter release from peripheral and central neuron (Hoyer, 1994). 
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Importantly, the function of this receptor depends on its localization. The activation of 
postsynaptic neuron 5-ht3 receptors is involved in fast synaptic transmission, while nerve-
terminal (presynaptic neuron) 5-ht3 receptors activation leads to release of 
neurotransmitters, like serotonin, dopamine or GABA. Thus, perturbed regulation of this 
particular genes is interesting because it has implications in (i) the regulation of synapses, 
for instance involved in fast synaptic transmission on postsynaptic neuron; (ii) the levels of 
neurotransmitters and their release of important neurotransmitters, as serotonin, 
dopamine, acetylcholine or GABA from presynaptic neurons to synaptic cleft. Release of 
these neurotransmitters in presynaptic neurons is crucial to active different receptors and 
modulates signals between neurons. In the experimental condition of PP exposure, which 
leads to an increase of monoamines in the synaptic cleft, the decreased receptor mRNA 
expression of 5-HT3A and 5-ht3b may be involved in the counter-regulation of serotonin 
level or desensitization. Considering the complex nature of monoamine systems and the 
interplay with other neurochemical system, numerous mechanisms may play a role in 
down regulation. Currently, reduced excitatory inputs or excessive self-inhibition by others 
serotonin receptors, as 5-ht1a, reduce serotonin synthesis and/or tryptophan deficit, as 
seen in mammals (Artigas, 2012b). From literature we know that in mammals the 
depression is attributable, at least in part, to abnormal transmission at central serotonin 
synapses (Andrews, 2015). Summarizing, we can suggest that the observed down-
regulation of 5-ht3a and 5-ht3b receptor mRNA expression can have effects on the fitness 
of aquatic animals with impact on their physiology as the ability to alter monoamines 
levels or neurotransmitter systems can inﬂuence diverse physiological processes in fish 
including: control of locomotor activity, appetite, reprodutive fitness, sleepor agreesion 
(Bisesi et al., 2014; Brooks et al., 2003; Mennigen et al., 2011, 2010; Menningen, 2011). 
Furthermore, the response to VEN antidepressant resulted in a unique and different 
gene expression profile. During the recovery period (without antidepressant exposure), 
the Dopamine D2 and D3 receptor, within D2-like subtypes, mRNA increased significantly 
at day 28 VEN or FLUX exerts its therapeutic effect by inhibiting monoamine transports 
reducing the reuptake of the serotonin or dopamine and activity of serotonin or dopamine 
transporter protein (SERT or DAT) at presynaptic neuronal membranes. We hypothesize 
that during the exposure with VEN the monoamine levels in the synaptic cleft were 
increased; the lack of reuptake inhibition should then lead to a decrease of previously 
elevated dopamine level. The mRNA expression of both dopamine receptors (D2; D3) was 
negatively correlated to the hypothesized change of dopamine level in the synaptic clefts, 
and may be related to an auto regulation to maintain high level of dopamine 
neurotransmission. It was reported that the presynaptic dopamine receptor, most of which 
belongs to the class D2-like, act as auto receptors (Vallone et al., 2000). These self-
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receptors recognize the density of dopamine from the synapse and reduce dopaminergic 
tone, decreasing the synthesis of dopamine in the presynaptic neuron and reducing 
neuronal discharge rate and the release of this monoamine (Harley, 2004).   
D2 receptor is thought to act predominantly as an auto receptor, and lower levels of 
expression may result in enhanced dopamine signaling (Sun et al., 2015). This study 
demonstrated that amphetamine self-administration decreased D2 receptor and increased 
D3 receptor mRNA level in ventral tegmental area or only increased the mRNA level of D3 
receptors in the nucleus accumbens without any effect on either D2 receptors.  
A previous study exposed Hybrid striped bass to VEN at concentrations of 50, 250, 
and 500 µg/L with a 6 day recovery period. At day 3 there was a significant increase of 
serotonin concentrations on brain that remained elevated for all treatments after 6 days of 
depuration (Bisesi et al., 2014) and could be related to inhibition of serotonin receptors. 
Studies had shown that dopamine plays a major role in aggression and social dominance. 
Following aggressive social interactions dopamine was shown to be decreased in the 
hippocampus of rainbow trout while increasing in the hypothalamus (Carpenter et al., 
2009).  
It is essential to regulate the neurotransmitters levels and theirs receptors in brain of 
organism, because the neurotransmitters play an important role in organism fitness. So, in 
our study was crucial understand if in response to VEN there were significant recovery in 
dopamine D2 and D3 after depuration time, or significant increase in response to FLUX at 
first day of exposure, leading to regular neurotransmission signals in European seabass 
that could alter the fitness of the species.  
The present study showed for the first time the comparison of mRNA expression of 
neurotransmitter genes and receptor subunits in response to the exposure to a SSRI and 
a SNRI in the brain of a marine fish species, D. labrax. As we have observed in the gene 
expression pattern, both pharmaceutical have unique and differently profile. The effects of 
VEN appeared after 21 days of exposure and had specific effects on serotonin and 
dopamine receptor subunits. In contrast, the effects of FLUX appeared only at day 1 of 
exposure, and affected all analyzed neurotransmitter genes and receptors.  
 
 
2.5. CONCLUSION  
The present work aimed to identify changes on neurotransmitters gene and 
receptors of serotonin or dopamine changes in transcription levels that could be useful for 
the considerations of potential effects in fish species fitness.  
The multiple alignment of the amino acid sequences for sert, 5-ht3a and 5-ht3b 
receptors, dopamine d2 and d3 receptors, mao and vmat in D. labrax with other vertebrate 
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species including human showed high degrees of homology of the identified transcripts. 
The observed sequence similarity allows the speculation that compounds could affect 
similar targets in non-model species, as we analyzed in the marine fish species D. labrax. 
The results on gene expression can indicate that environmental exposure to 
antidepressants may adversely affect aquatic species triggering behavioral disorders and 
aggravating the fitness. Furthermore, the sequence homology and the wide geographical 
distribution range make European Sea bass an interesting candidate as a sentinel species 
for environmental field studies.  
The antidepressants share a common pharmacological activity, despite in our 
results they do not share common effects on analyzed neurotransmitter genes and 
receptors. First, the response to VEN was specific and selected to some target genes, 
since significant effects of antidepressants were observed in several target genes. It was 
detected a chronic induction mainly of the serotonin receptor 5-ht3a and 5-ht3b at 21 day.  
Regarding dopamine receptors, d2 and d3 were significantly recovered in time of 
depuration. In contrast with FLUX, all neurotransmitter genes and receptors were 
significantly regulated by the contaminant at first day of exposure, leading to an acute 
induction of gene expression. The presented data indicate that both antidepressants have 
different molecular mechanisms in a non-target species.  
The D. labrax was used for the first time as a representative of a marine fish species 
for the analysis of chronic effects of PP on the neurotransmitter system. This is 
particularity true because until nowadays only research in freshwater fish was present 
dealing with effects of PP. But, an increasing number of scientists are taking advantage of 
marine organisms as models to investigate questions in biology. The chosen marine 
species, D. labrax, is an economically important species of fish, which increases the 
relevance of this study. Observed neuronal changes could have major impact on 
European seabass, and may finally lead to alterations on their fitness.  
Hence, the qPCR-RT analysis revealed the potency of SSRI and SNRI in 
modulating expression of genes involved in neurotransmission response pathways. 
Changes in the expression of the target gene were useful as biomarker of effects of 
chronic exposure to SSRI or SNRI. Data indicate the need to test pharmaceutical 
compounds individually, in order to provide a toxicological risk assessment.  
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3.1. FINAL REMARKS 
3.1.1. General discussion 
  In the last decades, aquatic pollution by pharmaceuticals has been recognized as 
a global environmental problem, jeopardizing the survival rates of many species. They 
have become predominantly detected in aquatic environments across North America and 
Europe leading to chronic effects on aquatic species. Thus, the understanding of the 
subjacent parameters of transcription levels of genes involved in neurotransmitter system 
is an uppermost need, as it can provide environmentalists with crucial information that 
may allow a sustainable future for the environment, because with a particular gene 
transcription level we can know whether the aquatic animal are to be chronically exposed 
to a PP.   
In this study we confirm that sert, 5-ht3b, dopamine d3, vmat has higher degree of 
homology with D.rerio, O.latipes, T.rubripes, including H. sapiens and that in a 
phylogenetic tree based on the multiple alignment analysis in all sequences are well 
clustered within each corresponding group. Thus, it is possible that the aquatic specie 
selected for this study, the European seabass, can be exploited as a sentinel species for 
environmental field studies.  
Expressional changes of neurotransmitters genes and receptors were determined 
upon FLUX and VEN exposure in European seabass. After the identification of the target 
partial sequences genes in this aquatic specie, we had to answer the question, whether 
PPs act differently on the neurotransmitters, by gene expression of dopamine and 
serotonin receptors, transporters specific and non-specific transporters and enzyme 
degrading measured by qPCR-RT.  
The chronic exposures were performed for 21 days, followed by a 7 day 
depuration period, to assess the reversibility of effects.  Different profiles of mRNA 
expression were obtained after exposure to SNRI and SSRI. Exposure to FLUX resulted 
in an acute response at day 1 in all analyzed target genes, except for the monoamine 
degrading enzyme, mao, which was increased after 21 days. Exposure to VEN caused 
significant differences at day 21 for the receptor of serotonin 5-ht3a. For both serotonin 
receptors lower mRNA level were detected, but only for 5-ht3a was significant different. 
Dopamine D2 and D3 receptors were significantly increased at 7 day of the recovery period. 
Hence, is very important to consider the potential for environmental SSRIs and 
SNRIs, because they act in human and fish altering monoamines concentration as can 
see in this study. They can alter the neurotransmission due to changes in transcription 
levels of gene expression of serotonin and dopamine receptors.  Activation of receptors 
on post-synaptic neurons opens ligand gated ion channels, which regulate the action 
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potential, and therefore, the signal transmission in neurons (Lodish et al., 2000). Due to 
the importance of neurotransmitters their increase understanding of the roles 
neurotransmitters plays in controlling fitness in fish.  
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3.1.2. Final conclusions/ Considerations 
The present dissertation demonstrated the potential of two classes of 
antidepressants, SSRI and SNRI, to differently regulate gene expression in European Sea 
bass brain. Of particular interest, FLUX acute induction was regulated significantly in all 
target genes and response to VEN was observed as a chronic tendency in all genes, 
suggesting that they affect different biological pathways despite their shared 
pharmacological use of inhibiting the reuptake of serotonin by blocking serotonin or 
dopamine receptors.  
These expression patterns indicate enrichment of human biological processes 
involving neurotransmission system. Thus, it can be made to biological processes 
associated with specific neurological disorders that have known or suspected 
environmental etiological components with others species or mammals. The elucidation of 
gene expression profiles for European Sea bass exposed to these SSRI and SNRI 
presents a unique comparison for other investigations on the effects of two classes of 
these antidepressants in fish and hypotheses for further research in fish physiology and 
the ecotoxicology of SSRIs or SNRIs present in aquatic environments.  
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Appendix I 
 
Samples types, country and concentrations reported of antidepressants 
PP 
 
Sample 
types 
Country 
Concentration 
reported 
(ng/L) 
Year Reference 
FLUX 
 Portuguese 
effluents 
Portugal 16,6-21,5 2014 
Silva et al., 
2014 
 WWTP 
influent 
Portugal <17-3645 2011 
Salgado et al, 
2011 
 WWTP 
influent 
Portugal <5 2011 
Sousa et al., 
2011 
 WWTP 
effluent 
Portugal <4 2011 
Sousa et al., 
2011 
 WWTP 
effluent 
Spain 19-929 2007 
Bueno et al., 
2007 
 WWTP 
influent 
Spain 26 2009 
Gros et al., 
2009 
 WWTP 
effluent 
Spain 16 2009 
Gros et al., 
2009 
 Hospital 
Effluent 
Spain 4-100 2007 
Gomez et al., 
2007 
 
Ebro river Spain 3 2009 
Gros et al., 
2009 
 
Jarama River Spain 13-16 2010 
Alonso et al., 
2010 
 
Manzanares Spain 22  
Alonso et al., 
2010 
 River 
Guadarrama 
Spain 13-120 2010 
Alonso et al., 
2010 
 River 
Henares 
Spain 11 2010 
Alonso et al., 
2010 
 
River Tajo Spain 12 2010 
Alonso et al., 
2010 
 WWTP 
efluent 
Canada 50-99 2003 
Metcalfe et 
al., 2003 
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 Peterborough, 
efluent 
Canada 50±5 2008 
Metcalfe et 
al., 2003 
 Burlington 
STP efluent 
Canada 38±3 2008 
Metcalfe et 
al., 2003 
 Hamilton 
Harbovir 
Canada 13±1 2008 
Metcalfe et 
al., 2003 
 Hamilton/Har
bor/Little 
River 
Canada 13-26 2008 
Lajeunesse et 
al., 2008 
 WWTP 
efluent 
Norway 0.6-8.4 2008 
Vasskog et 
al., 2008 
 
 
Streamf
low 
Boul
der Creek 
9±6 
2
010 
Schultz 
et al., 2010 
(b) 
 
 
Streamflow 
Fourmilw 
Creek 
4.4±0.5 2010 
Schultz et al., 
2010 (b) 
NorFLUX 
 WWTP 
influent 
Portugal <14-32.228 2011 
Salgado et al., 
2011 
 
 WWTP 
influent 
Portugal 45-105 2011 
Sousa et al., 
2011 
 WWTP 
effluent 
Portugal 60-240  
Silva et al., 
2014 
 WWTP 
effluent 
Spain 1141 2007 
Bueno et al., 
2007 
 WWTP 
influent 
Canada 11 2010 
Metcalfe et 
al., 2010 
VEN 
 
Effluent Texas 1310 2010 
Schultz et al., 
2010 
 
 
Streamflow 
Boulder 
Creek 
220±40 2010 
Schultz et al., 
2010 
 
 
Streamflow 
Fourmile 
Creek 
210±40 2010 
Schultz et al., 
2010 
  
 
Appendix II 
 
 
 
Exposure system of juvenile european Sea bass with FLUX and VEN. 
The reconstituted seawater is conducted to a peristaltic pump (B) in which it forwards to a mixing container 
(E). C) From the stock solution of antidepressants with different concentrations are forwarded to another peristaltic 
pump (D) and forwards to the mixing vessels (E). E) From the mixture of bottles with the concentration of the 
contaminant and reconstituted seawater is continuously distributed to each of the respective tanks. After a day 
acclimatization of the animals in the experimental system of fluoxetine 24 are added to each of the tanks 12 (3 
treatments with three replicas) with a total of 288 (G). In the case of venlafaxine 12 are added to each aquarium fish, 
with a total of 144 animals. 
 
 
 
 
 
 
  
 
Appendix III 
 
In the present study our attempts to develop PCR primers based on published 
sequences.  New sequences were defined from DNA available of the target sequences, 
as SERT, 5-HT3A, 5-HT3B, D2, D3, MAO and VMAT. The results defined all the intro and 
exons sizes of target sequences and the final length. From DNA was design primers 
removing the all the introns.  
 
Schematic representation of the genomic organization (DNA) of target sequences. The exact sizes of 
the exons and the introns are given the top of each partition.  
 
 
 
Appendix IV 
 
Electrophoresis analysis of PCR products amplified with selected primers in this study with 1.5% 
agarose gel.  
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Appendix V 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Electrophoresis analysis (1.5% agarose gel) to verify the quality of the samples. Molecular weight  
marker (100bp ladder). 1 Day of exposure: a) and b) RNA samples after was subjected to digestion of 
DNA genomic; c) and d) Total RNA. 21 day of exposure: a), b) and c) RNA samples after was subjected 
to digestion of DNA genomic; d), e), f), g) Total RNA. 28 day of exposure: a), b) and c) RNA samples 
after was subjected to digestion of DNA genomic; d), e), f), g) Total RNA.  
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Appendix VI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Electrophoresis analysis (1.5% agarose gel) to verify the quality of the samples. Molecular weight 
marker (100bp ladder). a) and b) RNA samples after was subjected to digestion of DNA genomic; c) 
and d) Total RNA.  
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